Multiplex detection of bacterial respiratory pathogens

JP2023547536A5Inactive Publication Date: 2024-11-11BECTON DICKINSON & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527012
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-05
Filing Date
2021-11-04
Publication Date
2024-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current diagnostic methods for bacterial respiratory pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae, are time-consuming, have low sensitivity, and often result in misidentification due to the use of suboptimal gene targets, especially in multiplex PCR assays.

Method used

Development of multiplex real-time PCR methods using specific primer pairs and probes that target conserved genes like lytA, cpsA, sodC, ctrA, nuc, fucK, copB, and gltA, along with an internal amplification control (IAC), allowing simultaneous detection of multiple pathogens with high sensitivity and specificity.

Benefits of technology

The method enables rapid, accurate detection of multiple bacterial pathogens in a single assay, reducing false positives and negatives by utilizing optimized gene targets and internal controls, thereby supporting timely antibiotic treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for detecting common bacterial pathogens that cause respiratory infections. In some embodiments, the presence or absence of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and / or Klebsiella pneumoniae in a sample is determined using a multiplex nucleic acid-based test.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Related Applications This application claims the benefit of PCT Application No. PCT / CN2020 / 126728, filed on November 5, 2020, the entire content of which is incorporated herein by reference in its entirety.

[0002] Sequence Listing This application is filed with a sequence listing in electronic format. The sequence listing is entitled 68EB-298736-WO2, created on November 2, 2021, and presented as a file with a size of 28 kb. The information on the electronic format of the sequence listing is incorporated herein by reference in its entirety. The present disclosure relates to methods and compositions for detecting bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae in a sample. More specifically, the present disclosure relates to the detection of one or more of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae in a sample such as a blood sample or a respiratory sample (or a culture thereof) by a nucleic acid-based assay method.

Background Art

[0003] Description of Related Technologies Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae are six common pathogens associated with respiratory tract infections. Acute bacterial respiratory tract infections are among the most common human illnesses. The severity of symptoms ranges from mild upper respiratory tract infections (URTIs) to severe lower respiratory tract infections (LRTIs), many of which are associated with marked morbidity and mortality, particularly in children, the elderly, and patients with underlying comorbidities such as immunodeficiency, congenital heart failure, or chronic respiratory disease. In addition, Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae are major pathogens frequently associated with bacterial meningitis, which accounts for more than 12 million cases worldwide annually. Klebsiella pneumoniae has been identified as a major nosocomial infection pathogen that can cause pneumonia, bronchitis, urinary tract infections, and wound infections. Furthermore, antibiotic-resistant Klebsiella pneumoniae, which has emerged in recent years, has become a serious problem in clinics. M. catarrhalis is one of the major bacterial pathogens that cause otitis media in children. M. catarrhalis also causes sinusitis, laryngitis, tracheitis, pneumonia, and other respiratory diseases in children and adults. The mortality rate from Staphylococcus aureus (S. aureus) infection and its complications is also high at 20%, and methicillin-resistant Staphylococcus aureus (MRSA) is one of the pathogens with the highest nosocomial infection rates, including intensive care unit infections and postoperative infections. Timely identification of all six of these pathogens originating from infected patients in cases of fever is important for supporting the appropriate use of antibiotics and controlling the disease.

[0004] Current standard diagnostic methods for respiratory bacteria are culture-based and typically require 24–72 hours. Culture methods are also low-sensitivity; for example, a positive microbiological diagnosis can only be made in about 30% of patients with community-acquired pneumonia. Furthermore, phenotypic errors can still occur, even when matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF MS) is used. Indeed, Cunningham et al. recently reported misidentification of N. polysaccharea strains as N. meningitidis using MALDI-TOF MS with high identification scores of 2.068–2.241. Such misidentification is predictable, as these two species are closely related, as evidenced by their high 16S rRNA identity percentages (99.3%).

[0005] Because a wide range of pathogens can cause respiratory tract infections, it is common to require a mixture of different diagnostic tests, including culture, antigen, and serological tests, for numerous different specimen types. In contrast, the use of PCR, such as multiplex PCR assays, can enable screening for multiple respiratory pathogens in a single respiratory specimen during the workday. In addition, PCR has many other advantages: high sensitivity and specificity, short result time, low labor intensity, and the ability to identify pathogens that grow slowly or are difficult to culture. Therefore, in order to effectively deliver appropriate treatment to patients, there is a need to develop more efficient and rapid methods for detecting bacterial respiratory pathogens, such as methods that enable the detection of more than two pathogens from among Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae in a single assay. In particular, there is a need for multiplex real-time PCR, which can simultaneously detect the aforementioned respiratory pathogens using more specific and comprehensive genetic markers. [Overview of the project]

[0006] This specification discloses methods for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the method involves contacting the sample with a plurality of primer pairs, wherein the plurality of primer pairs include at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 1 to 10, or any one of the sequences of SEQ ID NOs: 1 to 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 16 to 25, or any one of the sequences of SEQ ID NOs: 16 to 25. The step includes: at least one primer pair containing a sequence; at least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 31 to 39, or any one of the sequences of SEQ ID NOs. 31 to 39; and at least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 45 to 54, or any one of the sequences of SEQ ID NOs. 45 to 54. The method may include, if the sample contains either or both of Streptococcus pneumoniae and Neisseria meningitidis, the steps of producing a unit replication sequence of the lytA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the cpsA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the sodC gene sequence of Neisseria meningitidis, a unit replication sequence of the crtA gene sequence of Neisseria meningitidis, or any combination thereof, derived from the sample.The method may include the step of determining the presence or amount of one or more unit replication sequences in the sample as an indicator of the presence of one or both of Streptococcus pneumoniae and Neisseria meningitidis. The method may include the step of contacting the sample with at least one pair of control primers capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of SEQ ID NOs. 60-69 and 130-132, or to one of the sequences of SEQ ID NOs. 60-69 and 130-132; and the step of creating a unit replication sequence of the IAC derived from the sample; and the step of determining the presence or amount of the unit replication sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is contacted with a composition comprising multiple pairs of primers and at least one pair of control primers capable of hybridizing to the IAC.

[0007] In some embodiments, the sample is a biological sample or an environmental sample. In some embodiments, the environmental sample is obtained from food samples, beverage samples, paper surfaces, cloth surfaces, metal surfaces, wood surfaces, plastic surfaces, soil samples, freshwater samples, wastewater samples, saline samples, exposure to air or other gaseous samples, cultures of these, or any combination thereof. In some embodiments, the biological sample is obtained from tissue samples, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural fluid, serumoma, pus, skin swabs or mucosal surfaces, cultures of these, or any combination thereof. In some embodiments, the biological sample includes blood samples, respiratory samples, and / or cultures of these.

[0008] In some embodiments, the multiple primer pairs include a first primer containing the sequence of SEQ ID NOs: 1, 3, 5, 7, or 9; a second primer containing the sequence of SEQ ID NOs: 2, 4, 6, 8, or 10; a third primer containing the sequence of SEQ ID NOs: 16, 18, 20, 22, or 24; a fourth primer containing the sequence of SEQ ID NOs: 17, 19, 21, 23, or 25; a fifth primer containing the sequence of SEQ ID NOs: 31, 33, 35, 36, or 38; a sixth primer containing the sequence of SEQ ID NOs: 32, 34, 37, or 39; a seventh primer containing the sequence of SEQ ID NOs: 45, 47, 49, 51, or 53; and an eighth primer containing the sequence of SEQ ID NOs: 46, 48, 50, 52, or 54. In some embodiments, the multiple primer pairs include a ninth primer containing the sequence of SEQ ID NOs. 60, 62, 64, 66, 68, or 131, and a tenth primer containing the sequence of SEQ ID NOs. 61, 63, 65, 67, 69, 130, or 132.

[0009] In some embodiments, primer pairs capable of hybridizing to the lytA gene of Streptococcus pneumoniae are SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, or SEQ ID NOs: 9 and 10; primer pairs capable of hybridizing to the cpsA gene of Streptococcus pneumoniae are SEQ ID NOs: 16 and 17, SEQ ID NOs: 18 and 19, SEQ ID NOs: 20 and 21, SEQ ID NOs: 22 and 23, or SEQ ID NOs: 24 and 25; primer pairs capable of hybridizing to the sodC gene of Neisseria meningitidis are SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 32, SEQ ID NOs: 36 and 37, or SEQ ID NOs: 38 and 39; primer pairs capable of hybridizing to the crtA gene of Neisseria meningitidis are SEQ ID NOs: 45 and 46, SEQ ID NOs: 47 and 48, SEQ ID NOs: 49 and 50, SEQ ID NOs: 51 and 52, or SEQ ID NOs: 53 and 54. In some embodiments, control primer pairs capable of hybridizing to IAC are SEQ ID NOs: 60 and 61, 62 and 63, 64 and 65, 66 and 67, 68 and 69, 61 and 130, or 131 and 132. In some embodiments, the amplification is performed using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-persistent sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA). In some embodiments, the PCR is real-time PCR. In some embodiments, the PCR is quantitative real-time PCR (QRT-PCR). In some embodiments, each primer contains an exogenous nucleotide sequence.

[0010] In some embodiments, the step of determining the presence or amount of one or more unit replica sequences includes contacting the unit replica sequences with multiple oligonucleotide probes, where each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, each probe is flanked by complementary sequences at its 5' and 3' ends. In some embodiments, one of the complementary sequences includes a fluorescent moiety, and the other complementary sequence includes a fluorescent quenching moiety. In some embodiments, at least one of the multiple oligonucleotide probes includes both a fluorescent moiety and a fluorescent quenching moiety.

[0011] This specification discloses compositions for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the composition comprises at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 1 to 10, or any one of the sequences of SEQ ID NOs: 1 to 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 16 to 25, or any one of the sequences of SEQ ID NOs: 16 to 25. A primer pair comprising: at least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least approximately 85% identity to any one of the sequences of SEQ ID NOs. 31 to 39, or any one of the sequences of SEQ ID NOs. 31 to 39; and at least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least approximately 85% identity to any one of the sequences of SEQ ID NOs. 45 to 54, or any one of the sequences of SEQ ID NOs. 45 to 54. The composition may include at least one pair of control primers capable of hybridizing to an internal amplification control (IAC), wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of sequence numbers 60-69 and 130-132, or to one of the sequences of sequence numbers 60-69 and 130-132.

[0012] In some embodiments, at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae comprises a primer containing the sequence of SEQ ID NO: 1, 3, 5, 7, or 9, and a primer containing the sequence of SEQ ID NO: 2, 4, 6, 8, or 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae comprises a primer containing the sequence of SEQ ID NO: 16, 18, 20, 22, or 24, and a primer containing the sequence of SEQ ID NO: 17, 19, 21, 23, or 25. The following are included: at least one primer pair capable of hybridizing to the meningococcal sodC gene, comprising a primer containing the sequence of SEQ ID NO: 31, 33, 35, 36, or 38, and a primer containing the sequence of SEQ ID NO: 32, 34, 37, or 39; at least one primer pair capable of hybridizing to the meningococcal crtA gene, comprising a primer containing the sequence of SEQ ID NO: 45, 47, 49, 51, or 53, and a primer containing the sequence of SEQ ID NO: 46, 48, 50, 52, or 54. In some embodiments, at least one control primer pair capable of hybridizing to IAC, comprising a primer containing the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a primer containing the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

[0013] The composition may contain multiple oligonucleotide probes, in which case each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. In some embodiments, at least one of several types of probes includes a fluorescent emission portion and a fluorescent quenching portion.

[0014] This specification discloses methods for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the method involves contacting the sample with a plurality of primer pairs, wherein each primer pair comprises at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 75-83, or any one of the sequences of SEQ ID NOs. 75-83; and at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, and each primer in the at least one primer pair exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 88-95, or any one of the sequences of SEQ ID NOs. 88-95. The step includes: at least one primer pair comprising a row; at least one primer pair capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 101 to 110 or any one of the sequences of SEQ ID NOs. 101 to 110; and at least one primer pair capable of hybridizing to the glTA gene of Klebsiella pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 116 to 124 or any one of the sequences of SEQ ID NOs. 116 to 124.The method may include, if the sample contains one or more species from Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae, the step of producing a unit replication sequence of the nuc gene sequence of Staphylococcus aureus, a unit replication sequence of the fucK gene sequence of Haemophilus influenzae, a unit replication sequence of the copB gene sequence of M. catarrhalis, a unit replication sequence of the gltA gene sequence of Klebsiella pneumoniae, or any combination thereof, derived from the sample. The method may also include the step of determining the presence or amount of one or more unit replication sequences of one or more species from Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in the sample as an indicator of the presence of one or more species. The method may include the steps of: contacting a sample with at least one pair of control primers capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer in the pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of SEQ ID NOs. 60-69 and 130-132, or to one of the sequences of SEQ ID NOs. 60-69 and 130-132; creating a unit replica sequence of the IAC derived from the sample; and determining the presence or amount of the unit replica sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is contacted with a composition containing multiple pairs of primers and at least one pair of control primers capable of hybridizing to the IAC.

[0015] In some embodiments, the sample is a biological sample or an environmental sample. In some embodiments, the environmental sample is obtained from food samples, beverage samples, paper surfaces, cloth surfaces, metal surfaces, wood surfaces, plastic surfaces, soil samples, freshwater samples, wastewater samples, saline samples, exposure to air or other gaseous samples, cultures of these, or any combination thereof. In some embodiments, the biological sample is obtained from tissue samples, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural fluid, serumoma, pus, skin swabs or mucosal surfaces, cultures of these, or any combination thereof. In some embodiments, the biological sample includes blood samples, respiratory samples, and / or cultures of these.

[0016] In some embodiments, the multiple primer pairs include a first primer containing the sequence of SEQ ID NOs. 75, 77, 79, 81, or 83; a second primer containing the sequence of SEQ ID NOs. 76, 78, 80, or 82; a third primer containing the sequence of SEQ ID NOs. 88, 90, 92, 93, or 94; a fourth primer containing the sequence of SEQ ID NOs. 89, 91, or 95; a fifth primer containing the sequence of SEQ ID NOs. 101, 103, 105, 107, or 109; a sixth primer containing the sequence of SEQ ID NOs. 102, 104, 106, 108, or 110; a seventh primer containing the sequence of SEQ ID NOs. 116, 118, 120, or 122; and an eighth primer containing the sequence of SEQ ID NOs. 117, 119, 121, 123, or 124. In some embodiments, the multiple primer pairs include a ninth primer containing the sequence of SEQ ID NOs. 60, 62, 64, 66, 68, or 131, and a tenth primer containing the sequence of SEQ ID NOs. 61, 63, 65, 67, 69, 130, or 132.

[0017] In some embodiments, primer pairs capable of hybridizing to the nuc gene of Staphylococcus aureus are SEQ ID NOs. 75 and 76, SEQ ID NOs. 77 and 78, SEQ ID NOs. 79 and 80, SEQ ID NOs. 81 and 82, or SEQ ID NOs. 83 and 78; primer pairs capable of hybridizing to the fucK gene of Haemophilus influenzae are SEQ ID NOs. 88 and 89, SEQ ID NOs. 90 and 91, SEQ ID NOs. 92 and 89, SEQ ID NOs. 93 and 89, or SEQ ID NOs. 94 and 95; M. cata Primer pairs capable of hybridizing to the copB gene of *Laris* are SEQ ID NOs: 101 and 102, SEQ ID NOs: 103 and 104, SEQ ID NOs: 105 and 106, SEQ ID NOs: 107 and 108, or SEQ ID NOs: 109 and 110; primer pairs capable of hybridizing to the glTA gene of *Klebsiella pneumoniae* are SEQ ID NOs: 116 and 117, SEQ ID NOs: 118 and 119, SEQ ID NOs: 120 and 121, SEQ ID NOs: 122 and 123, or SEQ ID NOs: 116 and 124. In some embodiments, control primer pairs capable of hybridizing to IAC are SEQ ID NOs: 60 and 61, SEQ ID NOs: 62 and 63, SEQ ID NOs: 64 and 65, SEQ ID NOs: 66 and 67, SEQ ID NOs: 68 and 69, SEQ ID NOs: 61 and 130, or SEQ ID NOs: 131 and 132.

[0018] In some embodiments, the amplification is performed using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-persistent sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA). In some embodiments, the PCR is real-time PCR. In some embodiments, the PCR is quantitative real-time PCR (QRT-PCR). In some embodiments, each primer contains an exogenous nucleotide sequence.

[0019] In some embodiments, the step of determining the presence or amount of one or more unit replica sequences includes contacting the unit replica sequences with multiple oligonucleotide probes, where each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each probe is flanked by complementary sequences at its 5' and 3' ends. In some embodiments, one of the complementary sequences includes a fluorescent moiety, and the other complementary sequence includes a fluorescent quenching moiety. In some embodiments, at least one of the multiple oligonucleotide probes includes both a fluorescent moiety and a fluorescent quenching moiety.

[0020] This specification discloses compositions for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the composition comprises at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 75-83 or any one of the sequences of SEQ ID NOs. 75-83; and at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 88-95 or any one of the sequences of SEQ ID NOs. 88-95. A pair of at least one primers capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer in the pair of at least one primers contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 101 to 110, or any one of the sequences of SEQ ID NOs. 101 to 110; and a pair of at least one primers capable of hybridizing to the glTA gene of Klebsiella pneumoniae, wherein each primer in the pair of at least one primers contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 116 to 124, or any one of the sequences of SEQ ID NOs. 116 to 124. The composition may include at least one pair of control primers capable of hybridizing to an internal amplification control (IAC), wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of sequence numbers 60-69 and 130-132, or to one of the sequences of sequence numbers 60-69 and 130-132.

[0021] In some embodiments, at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus comprises a primer containing the sequence of SEQ ID NO: 75, 77, 79, 81, or 83, and a primer containing the sequence of SEQ ID NO: 76, 78, 80, or 82; at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae comprises a primer containing the sequence of SEQ ID NO: 88, 90, 92, 93, or 94, and a primer containing the sequence of SEQ ID NO: 89, 91, or 95; M. Cataler At least one primer pair capable of hybridizing to the squirrel copB gene comprises a primer containing the sequence of SEQ ID NO: 101, 103, 105, 107, or 109, and a primer containing the sequence of SEQ ID NO: 102, 104, 106, 108, or 110; at least one primer pair capable of hybridizing to the Klebsiella pneumoniae gltA gene comprises a primer containing the sequence of SEQ ID NO: 116, 118, 120, or 122, and a primer containing the sequence of SEQ ID NO: 117, 119, 121, 123, or 124. In some embodiments, at least one control primer pair capable of hybridizing to IAC comprises a primer containing the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a primer containing the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

[0022] The composition may contain multiple oligonucleotide probes, in which case each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, at least one of the multiple probes includes a fluorescent portion and a fluorescent quenching portion.

[0023] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the lytA gene of Streptococcus pneumoniae. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 15, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 15. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 15, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 15. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 15.

[0024] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the cpsA gene of Streptococcus pneumoniae. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 16 to 30, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 16 to 30.

[0025] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the sodC gene of Neisseria meningitidis. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 31-44, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 31-44. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 31-44, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 31-44. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 31-44.

[0026] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the crtA gene of Neisseria meningitidis. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 45-59, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 45-59.

[0027] This specification discloses probes or primers of about 100 nucleotides or less in length that can be hybridized to an internal amplification control (IAC). In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134.

[0028] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the nuc gene of Staphylococcus aureus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 75 to 87, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 75 to 87.

[0029] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the fucK gene of Haemophilus influenzae. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 88 to 100, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 88 to 100. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 88 to 100, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 88 to 100. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 88 to 100.

[0030] This specification discloses probes or primers of about 100 nucleotides or less in length that can hybridize to the copB gene of M. catarrhalis. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 101 to 115, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 101 to 115. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 101 to 115, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 101 to 115. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 101 to 115.

[0031] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the gltA gene of Klebsiella pneumoniae. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 116-129, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 116-129. This specification discloses compositions. In some embodiments, the composition comprises two or more oligonucleotide probes and / or primers from among those disclosed herein. [Modes for carrying out the invention]

[0032] The following detailed description will refer to the accompanying drawings, which form part of this specification. In the drawings, unless otherwise indicated by the context, similar symbols typically identify similar components. The exemplary embodiments described in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be utilized and other variations may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that all aspects of the disclosure described herein and illustrated in the drawings may be arranged, substituted, combined, separated, and designed in a wide variety of different configurations that are expressly assumed herein and constitute part of this disclosure herein.

[0033] With regard to the relevant technologies, all patents, patent application publications, other publications, and arrangements in GenBank and other databases referred to herein are incorporated in their entirety by reference. Because a wide range of pathogens can cause respiratory tract infections, it is common to require a mixture of different diagnostic tests, including culture tests, antigen tests, and serological tests, for numerous different specimen types. In contrast, the use of PCR, particularly multiplex PCR assays, can enable screening for multiple respiratory pathogens in a single respiratory specimen during the workday. In addition, PCR has many other advantages: high sensitivity and specificity, short result time, low labor intensity, and the ability to identify pathogens that grow slowly or are difficult to culture.

[0034] While prior art has described PCR methods adapted to some common respiratory bacteria, assays rarely target the broad range of Gram-positive and Gram-negative pathogens required for respiratory tract infection diagnosis. Ouattara, M et al. (Diagnostic microbiology and infectious disease 93.3 2019: 188-190.) described a real-time PCR method using a Taqman probe capable of detecting only Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Hasan, M. R et al. (Journal of virological methods 265 2019: 42-48) described a singleplex real-time PCR set using two sets of eight-tube strips for detecting Streptococcus pneumoniae, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and other respiratory viruses. Furthermore, some assays lack sensitivity and / or specificity for organisms such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae due to the use of suboptimal gene targets. For Neisseria meningitidis, several RT-PCR assays target ctrA, a transport gene in the capsule. However, the fact that more than 16% of isolates from Neisseria meningitidis carriers lack ctrA renders this target gene ineffective in identifying subpopulations of this Neisseria meningitidis isolate. The sodC gene is also specific to Neisseria meningitidis and could therefore offer an alternative target. However, PCR for sodC has been suggested to be less sensitive than that for ctrA. Target genes for detecting Streptococcus pneumoniae include the pneumolysin (ply) gene, the autolysin (lytA) gene, and the 16S rRNA gene.However, because respiratory microbiota (e.g., Streptococcus mitis and Streptococcus oralis) sometimes contain the ply gene, false positive results have been reported with ply-based PCR when applied to upper respiratory tract specimens. In addition, Streptococcus pneumoniae shares over 99% 16S rRNA gene identity with S. mitis and S. oralis. The hpd target, the protein D coding gene commonly used for Haemophilus influenzae, was known to cross-react with Haemophilus aphrophilus. Inclusion is a key influencing factor when detecting Klebsiella pneumoniae, given the presence of three distinctly different lineages called KpI, KpII, and KpIII (KpI being the most frequently observed). Two new bacterial species, K. variicola and K. quasipneumoniae, were identified, along with corresponding KpIII and KpII genes. These bacterial species, like Klebsiella pneumoniae, are generally multidrug resistant and may possess cephalosporinase or carbapenemase genes. For effective care delivery and clinical utility to be achieved, target genes must be conserved across all three pathogens. However, the commonly used marker, gapA gene, can only be detected in KPI and KPIII.

[0035] Therefore, in order to effectively deliver appropriate treatment to patients, there is a need to develop more efficient and rapid methods for detecting respiratory pathogens, such as methods that enable the detection of more than two pathogens from among Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae in a single assay. In particular, there is a need for multiplex real-time PCR methods that can simultaneously detect the aforementioned respiratory pathogens using more specific and comprehensive genetic markers.

[0036] This specification presents methods and compositions for detecting bacterial respiratory pathogens. For example, primers and probes are provided that can bind to specific genes of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae to determine the presence or absence of these pathogens in a sample such as a biological sample. In some embodiments, multiplex nucleic acid amplification may be performed to enable the detection of Streptococcus pneumoniae and Neisseria meningitidis in a single assay, and / or to enable the detection of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a single assay.

[0037] This specification discloses methods for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the method involves contacting the sample with a plurality of primer pairs, wherein the plurality of primer pairs include at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 1 to 10, or any one of the sequences of SEQ ID NOs: 1 to 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 16 to 25, or any one of the sequences of SEQ ID NOs: 16 to 25. The step includes: at least one primer pair containing a sequence; at least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 31 to 39, or any one of the sequences of SEQ ID NOs. 31 to 39; and at least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 45 to 54, or any one of the sequences of SEQ ID NOs. 45 to 54. The method may include, if the sample contains either or both Streptococcus pneumoniae and Neisseria meningitidis, the step of producing a unit replication sequence of the lytA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the cpsA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the sodC gene sequence of Neisseria meningitidis, a unit replication sequence of the crtA gene sequence of Neisseria meningitidis, or any combination thereof, derived from the sample.The method may include the step of determining the presence or amount of one or more unit replication sequences in the sample as an indicator of the presence of one or both of Streptococcus pneumoniae and Neisseria meningitidis. The method may include the step of contacting the sample with at least one pair of control primers capable of hybridizing with an internal amplification control (IAC) added to the sample, wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of SEQ ID NOs. 60-69 and 130-132, or to one of the sequences of SEQ ID NOs. 60-69 and 130-132; and the step of creating a unit replication sequence of the IAC derived from the sample; and the step of determining the presence or amount of the unit replication sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is contacted with a composition comprising multiple pairs of primers and at least one pair of control primers capable of hybridizing to the IAC.

[0038] This specification discloses compositions for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the composition comprises at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 1 to 10, or any one of the sequences of SEQ ID NOs: 1 to 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 16 to 25, or any one of the sequences of SEQ ID NOs: 16 to 25. A primer pair comprising: at least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least approximately 85% identity to any one of the sequences of SEQ ID NOs. 31 to 39, or any one of the sequences of SEQ ID NOs. 31 to 39; and at least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least approximately 85% identity to any one of the sequences of SEQ ID NOs. 45 to 54, or any one of the sequences of SEQ ID NOs. 45 to 54. The composition may include at least one pair of control primers capable of hybridizing with an internal amplification control (IAC), wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of sequence numbers 60-69 and 130-132, or to one of the sequences of sequence numbers 60-69 and 130-132.The composition may contain multiple oligonucleotide probes, in which case each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134.

[0039] This specification discloses methods for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the method involves contacting the sample with a plurality of primer pairs, wherein the plurality of primer pairs include at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 75-83, or any one of the sequences of SEQ ID NOs. 75-83; and at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, and each primer in the at least one primer pair exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 88-95, or any one of the sequences of SEQ ID NOs. 88-95. The step includes: at least one primer pair comprising a row; at least one primer pair capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 101 to 110 or any one of the sequences of SEQ ID NOs. 101 to 110; and at least one primer pair capable of hybridizing to the glTA gene of Klebsiella pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 116 to 124 or any one of the sequences of SEQ ID NOs. 116 to 124.The method may include, if the sample contains one or more species from Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae, the step of producing a unit replication sequence of the nuc gene sequence of Staphylococcus aureus, a unit replication sequence of the fucK gene sequence of Haemophilus influenzae, a unit replication sequence of the copB gene sequence of M. catarrhalis, a unit replication sequence of the gltA gene sequence of Klebsiella pneumoniae, or any combination thereof, derived from the sample. The method may also include the step of determining the presence or amount of one or more unit replication sequences of one or more species from Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in the sample as an indicator of the presence of one or more species. The method may include the steps of: contacting a sample with at least one pair of control primers capable of hybridizing with an internal amplification control (IAC) added to the sample, wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of SEQ ID NOs. 60-69 and 130-132, or to one of the sequences of SEQ ID NOs. 60-69 and 130-132; producing a unit replica sequence of the IAC derived from the sample; and determining the presence or amount of the unit replica sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is contacted with a composition comprising multiple pairs of primers and at least one pair of control primers capable of hybridizing to the IAC.

[0040] This specification discloses compositions for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the composition comprises at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 75-83 or any one of the sequences of SEQ ID NOs. 75-83; and at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 88-95 or any one of the sequences of SEQ ID NOs. 88-95. A pair of at least one primers capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer in the pair of at least one primers contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 101 to 110, or any one of the sequences of SEQ ID NOs. 101 to 110; and a pair of at least one primers capable of hybridizing to the glTA gene of Klebsiella pneumoniae, wherein each primer in the pair of at least one primers contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs. 116 to 124, or any one of the sequences of SEQ ID NOs. 116 to 124. The composition may include at least one pair of control primers capable of hybridizing with an internal amplification control (IAC), wherein each primer in the at least one pair of control primers contains a sequence that exhibits at least about 85% identity to one of the sequences of sequence numbers 60-69 and 130-132, or to one of the sequences of sequence numbers 60-69 and 130-132.The composition may contain multiple oligonucleotide probes, in which case each of the multiple oligonucleotide probes contains a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the lytA gene of Streptococcus pneumoniae. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 1 to 15, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 15. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the cpsA gene of Streptococcus pneumoniae. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 16-30, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 16-30.

[0041] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the sodC gene of Neisseria meningitidis. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 31-44, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 31-44. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the crtA gene of Neisseria meningitidis. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 45-59, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 45-59.

[0042] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can be hybridized to an internal amplification control (IAC). In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 60-74 and 130-134. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the nuc gene of Staphylococcus aureus. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 75-87, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 75-87.

[0043] This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the fucK gene of Haemophilus influenzae. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 88-100, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 88-100. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the copB gene of M. catarrhalis. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 101-115, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 101-115. This specification discloses probes or primers, approximately 100 nucleotides or less in length, that can hybridize to the gltA gene of Klebsiella pneumoniae. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 116-129, or a sequence exhibiting at least approximately 85% identity to a sequence selected from the group consisting of SEQ ID NOs. 116-129. This specification discloses compositions. In some embodiments, the composition comprises one or more oligonucleotide probes and primers, or two or more oligonucleotide probes and primers, from among those disclosed herein.

[0044] definition As used herein, the term “nucleic acid” may refer to a polynucleotide sequence or a fragment thereof. Nucleic acids may contain nucleotides. Nucleic acids may be exogenous or endogenous to cells. Nucleic acids may exist in a cell-free environment. Nucleic acids may be genes or fragments thereof. Nucleic acids may be DNA. Nucleic acids may be RNA. Nucleic acids may contain one or more analogues (e.g., modified skeletons, sugars, or nucleobases). Some non-limiting examples of analogs include 5-bromouracil, peptide nucleic acids, xeno nucleic acids, morpholino, loct nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to sugars), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queosin, and viosin. The terms "nucleic acid," "polynucleotide," "targeted polynucleotide," "targeted nucleic acid," and "targeted sequence" may be used interchangeably. As used herein, "nucleic acid" may refer to polymer compounds containing nucleosides or nucleoside analogs having nitrogenous heterocyclic bases or base analogs linked together by nucleic acid backbone linkages (e.g., phosphodiester bonds) to form a polynucleotide. Non-limiting examples of nucleic acids include RNA, DNA, and their analogues. The nucleic acid backbone may include one or more of various linkages, e.g., sugar-phosphodiester linkages, peptide-nucleic acid linkages, phosphorothioate linkages or methylphosphonate linkages, or mixtures of such linkages within a single oligonucleotide. The sugar portion within a nucleic acid may be ribose, deoxyribose, or similar compounds with known substitutions. The term nucleic acid includes conventional nitrogenous bases (e.g., A, G, C, T, U), known base analogues (e.g., inosine), derivatives of purine or pyrimidine bases, and “non-basic” residues (i.e., no nitrogenous bases found at one or more backbone positions).In other words, nucleic acids may consist only of the conventional sugars, bases, and ligatures found within RNA and DNA, or they may consist of both conventional components and substitutions (for example, conventional bases and analogues linked via a methoxy backbone, or conventional bases and one or more base analogues linked via an RNA backbone or a DNA backbone).

[0045] Nucleic acids may contain one or more modifications (e.g., base modifications, skeletal modifications) to give them new or enhanced characteristics (e.g., improved stability). Nucleic acids may contain nucleic acid affinity tags. Nucleosides can be base-sugar combinations. The base portion of a nucleoside can be a heterocyclic base. Two of the most common classes of such heterocyclic bases are purines and pyrimidines. A nucleotide can be a nucleoside that further contains a phosphate group covalently linked to the sugar portion of the nucleoside. In nucleosides containing pentofuranosyl sugars, the phosphate group may be linked to the 2'-hydroxyl, 3'-hydroxyl, or 5'-hydroxyl portion of the sugar. In nucleic acid formation, phosphate groups can covalently link adjacent nucleosides to each other to form linear polymer compounds. Next, each end of this linear polymer compound can be further linked to form a cyclic compound, although linear compounds are generally preferred. In addition, linear compounds can have nucleotide base complementarity internally, so they can fold in a way that results in fully double-stranded or partially double-stranded compounds. Within nucleic acids, phosphate groups are generally said to form the internucleoside skeleton of the nucleic acid. The linkage or skeleton can be a 3'-5' phosphodiester linkage.

[0046] Nucleic acids may contain modified skeletons and / or modified nucleoside linkages. Modified skeletons may contain phosphorus atoms or may not contain phosphorus atoms. Appropriately modified nucleic acid skeletons containing a phosphorus atom may include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methylphosphonates, and other alkylphosphonates, phosphomidates, phosphorodiamidates, thionophosphoramideates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates, which have, for example, normal 3'-5' linkages, their 2'-5' linkage analogs, and analogs with opposite polarity where one or more internucleotide linkages are 3'-3' linkages, 5'-5' linkages, or 2'-2' linkages, as well as phosphoramidates, phosphorodiamidates, thionophosphoramideates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates, which include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates, which include phosphoramidates, phosphoramidates, thionophosphoramideates, and aminoalkylphosphoramideates, such as 3'-alkylenephosphonates, 5'-alkylenephosphonates, and chiral phosphonates.

[0047] Nucleic acids may include polynucleotide skeletons formed by nucleoside linkages of short-chain alkyl or cycloalkyl molecules, nucleoside linkages of mixed heteroatoms and alkyl or cycloalkyl molecules, or nucleoside linkages of one or more short chains accompanied by heteroatoms or heterocycles. These polynucleotide skeletons include polynucleotide skeletons having morpholino linkages (partially formed from the sugar portion of the nucleoside); siloxane skeletons; sulfide skeletons, sulfoxide skeletons, and sulfone skeletons; formacetyl skeletons and thioformacetyl skeletons; methyleneformacetyl skeletons and thioformacetyl skeletons; riboacetyl skeletons; alkene-containing skeletons; sulfamate skeletons; methyleneimino skeletons and methylenehydrazino skeletons; sulfonate skeletons and sulfonamide skeletons; amide skeletons; and other polynucleotide skeletons in which N, O, S, and CH2 components are mixed.

[0048] Nucleic acids may include nucleic acid mimes. The term “mimetic” may refer to polynucleotides in which only the furanose ring or both the furanose ring and the internucleotide linkages are replaced by a group other than furanose; replacement of only the furanose ring may also be called a sugar surrogate. Heterocyclic base moieties or modified heterocyclic base moieties may be maintained for hybridization with a suitable target nucleic acid. One such nucleic acid may be a peptide nucleic acid (PNA). Within a PNA, the sugar backbone of a polynucleotide may be replaced by an amide-containing backbone, particularly an aminoethylglycine backbone. The nucleotide may be retained and may be directly or indirectly bonded to the aza nitrogen atom of the amide moiety of the backbone. The backbone within a PNA compound may contain two or more linked aminoethylglycine units that give the PNA an amide-containing backbone. The heterocyclic base moiety may be directly or indirectly bonded to the aza nitrogen atom of the amide moiety of the backbone.

[0049] Nucleic acids may contain a morpholino backbone structure. For example, a nucleic acid may contain a six-membered morpholino ring instead of a ribose ring. In some of these embodiments, phosphorodiamidate or other non-phosphodiester nucleoside linkages may replace phosphodiester linkages. Nucleic acids may contain linked morpholino units (e.g., morpholino nucleic acids) having heterocyclic bases linked to a morpholino ring. Linking groups can link morpholino monomer units within morpholino nucleic acids. Morpholino-based nonionic oligomeric compounds can reduce undesirable interactions with intracellular proteins. Morpholino-based polynucleotides can be nonionic mimetic forms of nucleic acids. Various compounds within the morpholino class can be linked using different linking groups. A further class of polynucleotide mimetic forms may be called cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in nucleic acid molecules can be replaced by a cyclohexenyl ring. CeNA DMT-protected phosphoramidite monomers can be prepared and used to synthesize oligomeric compounds using phosphoramidite chemical reactions. Incorporation of CeNA monomers into nucleic acid chains can increase the stability of DNA / RNA hybrids. The oligoadenylic acid of CeNA can form complexes with nucleic acid complements that exhibit stability similar to that of the natural complex. Further modifications may include located nucleic acids (LNA) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring, thereby forming a 2'-C,4'-C-oxymethylene linkage, which in turn forms a bicyclic sugar moiety. The linkage may be methylene (-CH2) [wherein n is 1 or 2], which is the group bridging the 2' oxygen atom and the 4' carbon atom. LNA and LNA analogs exhibit extremely high bichain thermal stability (T) with complementary nucleic acids. m At temperatures between +3 and +10°C, it can exhibit stability against degradation by 3'-exonucleases and good solubility.

[0050] Nucleic acids may also include modifications or substitutions of nucleobases (often simply referred to as "bases"). As used herein, "unmodified" or "natural" nucleobases may include purine bases (e.g., adenine (A), guanine (G)) and pyrimidine bases (e.g., thymine (T), cytosine (C), and uracil (U)). Modified nucleobases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, adenine and guanine, 6-methyl derivatives and other alkyl derivatives, adenine and guanine, 2-propyl derivatives and other alkyl derivatives, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and 5-halosytosine, 5-propynyl(-C=C-CH3)uracil and 5-propynyl(-C=C-CH3)cytosine, and other alkynyl derivatives of pyrimidine bases, 6-azouracil, 6-azocytosine and 6-azothimine, 5-uracil (pseudolacil), 4-thiouracil, 8-haloadenine and 8-haloguanine, 8-aminoadenine and 8-aminoguanine This may include other synthetic and natural nucleobases such as anine, 8-thioladenine and 8-thiolguanine, 8-thioalkyladenine and 8-thioalkylguanine, 8-hydroxyladenine and 8-hydroxylguanine, as well as other 8-substituted adenines and 8-substituted guanines, 5-halouracil and 5-halocytosine, in particular 5-bromouracil and 5-bromocytosine, 5-trifluoromethyluracil and 5-trifluoromethylcytosine, as well as other 5-substituted uracils and 5-substituted cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, as well as 3-deazaguanine and 3-deazaadenine.Modified nucleobases include tricyclic pyrimidines such as phenoxazinecytidine (1H-pyrimido(5,4-b)(1,4)benzoxazine-2(3H)-one) and phenothiazinecytidine (1H-pyrimido(5,4-b)(1,4)benzothiadin-2(3H)-one), substituted phenoxazinecytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazine-2(3H)-one), and phenothiazinecytidine (1H-pyrimido It may contain G-clamps such as (5,4-b)(1,4)benzothiazine-2(3H)-one), substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimide(5,4-(b)(1,4)benzoxadine-2(3H)-one), carbazole cytidine (2H-pyrimide(4,5-b)indole-2-one), and pyridoindole cytidine (H-pyrimide(3',2':4,5)pyrrolo[2,3-d]pyrimidine-2-one).

[0051] As used herein, the term “isolate nucleic acids” may refer to the purification of nucleic acids from one or more intracellular components. Those skilled in the art will understand that a sample processed to “isolate nucleic acids” from it may contain components and impurities other than nucleic acids. A sample containing isolated nucleic acids may be prepared from a sample using any acceptable method known in the art. For example, cells may be lysed using known lysis agents, and nucleic acids may be purified or partially purified from other intracellular components. Reagents and protocols suitable for DNA and RNA extraction can be found, for example, in U.S. Patent Application Publications US2010-0009351 and US2009-0131650, respectively (each of which is incorporated herein by reference in whole). In nucleic acid testing (e.g., amplification and hybridization methods, which are discussed in more detail below), the extracted nucleic acid solution may be directly added to reagents required to perform the test according to the embodiments disclosed herein (e.g., in liquid form, substrate-bound form, or lyophilized form, as discussed in more detail below).

[0052] As used herein, “template” may refer to all or part of a polynucleotide containing at least one target nucleotide sequence. As used herein, "primer" may refer to a polynucleotide that can be used to induce a nucleic acid chain elongation reaction. The length of the primer may vary, for example, from about 5 to about 100 nucleotides, from about 10 to about 50 nucleotides, from about 15 to about 40 nucleotides, or from about 20 to about 30 nucleotides. The length of the primer may be in the range of about 10 nucleotides, about 20 nucleotides, about 25 nucleotides, about 30 nucleotides, about 35 nucleotides, about 40 nucleotides, about 50 nucleotides, about 75 nucleotides, about 100 nucleotides, or between any two of these values. In some embodiments, the primer has a length of 10 to about 50 nucleotides, i.e., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more nucleotides. In some embodiments, the primer has a length of 18 to 32 nucleotides.

[0053] As used herein, "probe" may refer to a polynucleotide that, under conditions enabling hybridization, can hybridize (e.g., specifically) to a target sequence within a nucleic acid, thereby enabling the detection of the target sequence or amplified nucleic acid. The "target" of a probe generally refers to a sequence within an amplified nucleic acid sequence, or a subset thereof, that specifically hybridizes to at least a portion of the probe oligomer via standard hydrogen bonding (i.e., base pairing). A probe may include a target-specific sequence and other sequences that contribute to the three-dimensional conformation of the probe. Sequences are "sufficiently complementary" if they enable stable hybridization of the probe oligomer to a target sequence that is not perfectly complementary to the probe's target-specific sequence under appropriate hybridization conditions. The length of a probe may vary, for example, from about 5 to about 100 nucleotides, about 10 to about 50 nucleotides, about 15 to about 40 nucleotides, or about 20 to about 30 nucleotides. The probe length may be in the range of approximately 10 nucleotides, approximately 20 nucleotides, approximately 25 nucleotides, approximately 30 nucleotides, approximately 35 nucleotides, approximately 40 nucleotides, approximately 50 nucleotides, approximately 100 nucleotides, or between any two of these values. In some embodiments, the probe has a length of 10 to approximately 50 nucleotides. For example, the primer and / or probe may be at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides, or longer. In some embodiments, the probe may be non-sequence-specific.

[0054] Preferably, the primer and / or probe may be between 8 and 45 nucleotides in length. For example, the primer and / or probe may be at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or more nucleotides in length. The primer and probe may be modified to contain additional nucleotides at the 5' end, the 3' end, or both. Those skilled in the art will understand that the additional bases at the 3' end of the amplification primer (not necessarily the probe) are generally complementary to the template sequence. The primer and probe sequences may also be modified to remove nucleotides at the 5' or 3' end. Those skilled in the art will understand that, in order to function for amplification, the primer or probe is one of the minimum length and annealing temperature primers or probes disclosed herein.

[0055] The primer and probe have a melting point (T m They can bind to their targets at an annealing temperature that is below ). m "Melting point" and "T" are interchangeable terms referring to the temperature at which 50% of a group of double-stranded polynucleotide molecules dissociate into single strands. In this technical field, the T of polynucleotides m A formula for calculating T is well known. For example, T m This is expressed by the following formula: T m The T of a hybrid polynucleotide can be calculated by =69.3 + 0.41 × (G + C)% / L [where L is the length of the probe within the nucleotide]. m It can also be estimated using the formula [(number of A+Ts)×2℃+(number of G+Cs)×4℃], which is derived from a hybridization assay in 1M salt, and generally, the T of PCR primers mcan be used to calculate. For example, see C. R. Newton et al. PCR, 2nd ed., Springer-Verlag (New York: 1997), p.24 (incorporated herein by reference in its entirety). In the art, for the calculation of T m there are other more refined calculation methods that take into account sequence features in addition to structural features. The melting point of an oligonucleotide can depend on the complementarity between the oligonucleotide primer or probe and the binding sequence and the salt conditions. In some embodiments, the oligonucleotide primers or probes presented herein have a T m less than about 90°C, for example, in a buffer with 50 mM KCl, 10 mM Tris-HCl, in the range between any two of the recited values, such as about 89°C, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39°C, or less.

[0056] In some embodiments, the primers disclosed herein, such as amplification primers, can be provided as an amplification primer pair, including, for example, a forward primer and a reverse primer (a first amplification primer and a second amplification primer). Preferably, the forward primer and the reverse primer have a T m that differs by less than 10°C, for example, less than 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4°C, 3°C, 2°C, or 1°C.

[0057] Provided that the oligonucleotide contains sufficient complementarity to specifically hybridize with the target nucleic acid sequence, the primer and probe sequences may be modified by having nucleotide substitutions (compared to the target sequence) within the oligonucleotide sequence. In this way, at least 1, 2, 3, 4, or about 5 nucleotides or less may be substituted. As used herein, the term “complementarity” may refer to sequence complementarity between regions of two polynucleotide chains, or between two regions of the same polynucleotide chain. When the two regions are arranged antiparallel, the first region of the polynucleotide is complementary to the second region of the same or different polynucleotide, and at least one nucleotide of the first region can base pair with a base of the second region. Therefore, it is not required that the two complementary polynucleotides base pair at every nucleotide position. "Fully complementary" may refer to a first polynucleotide that is 100% complementary to a second polynucleotide, or "fully" complementary, and therefore forms base pairs at every nucleotide position. "Partially complementary" may also refer to a first polynucleotide that is not 100% complementary (e.g., 90%, 80%, or 70%) and contains mismatched nucleotides at one or more nucleotide positions. In some embodiments, the oligonucleotide contains a universal base.

[0058] As used herein, “exogenous nucleotide sequence” may refer to sequences introduced by a primer or probe used for amplification such that the amplification product contains the exogenous nucleotide sequence and the target nucleotide sequence in a configuration not found in the original template from which the target nucleotide sequence was copied. When applied to nucleic acid molecules, as used herein, “sequence identity” or “~ percent identical” may refer to the percentage of nucleic acid residues within a candidate nucleic acid molecule sequence that are identical to the target nucleic acid molecule sequence, after the sequences have been aligned to achieve the maximum identity percentage and all nucleic acid residue substitutions have not been considered as part of sequence identity. Nucleic acid sequence identity can be determined using any method known in the art, such as CLUSTALW, T-COFFEE, or BLASTN.

[0059] As used herein, “sufficiently complementary” may refer to a sequence of nucleic acid bases that can hybridize to another base sequence through hydrogen bonding between a series of complementary bases. A complementary base sequence may be complementary at each position within the oligomeric sequence using standard base pairings (e.g., G:C, A:T, or A:U pairings), or it may contain one or more residues that are not complementary (including non-basic positions), in which case the entire complementary base sequence can specifically hybridize to another base sequence under appropriate hybridization conditions. A sequence of bases may be at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% complementary to the sequence in which the oligomer is intended to hybridize. A substantially complementary sequence may refer to a sequence in which the percentage of identity, compared to the reference sequence, is in the range of 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75, 70 or less, or any number in between. A person skilled in the art can easily select appropriate hybridization conditions, which may be predicted based on the composition of the base sequence, or determined by using prescribed tests. (For example, see Green and Sambrook, Molecular Cloning, A Laboratory Manual, 4th ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012)). As used herein, the term “multiplex PCR” refers to a type of PCR in which one or more primer sets are included in a reaction that allows a single target, or two or more different targets, to be amplified in a single reaction vessel (e.g., a test tube). Multiplex PCR can be, for example, real-time PCR.

[0060] Oligonucleotides and compositions containing them As described herein, nucleic acid amplification may be performed to determine the presence, absence, type, and / or level of bacterial respiratory pathogens in a sample, such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae. In some embodiments, the presence, absence, and / or level of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae, as well as the presence, absence, and / or level of Streptococcus pneumoniae and Neisseria meningitidis, is determined by detecting one or more target genes of each of the target organisms using methods known in the art, such as DNA amplification. In some embodiments, multiplex PCR may be performed to detect the presence, absence, or level of each of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae. In some embodiments, multiplex PCR is performed to detect the presence, absence, and / or level of Streptococcus pneumoniae and Neisseria meningitidis, respectively.

[0061] In some embodiments, each of the target pathogenic bacteria disclosed herein may be detected using a separate channel in DNA amplification. In some embodiments, it may be desirable to use a single fluorescence channel to detect the presence, absence, and / or levels of two or more bacterial respiratory pathogens. For example, a single fluorescence channel may be used to detect the presence, absence, and / or levels of two or more bacterial respiratory pathogens. In some embodiments, such combinations may reduce the amount of reagents required to perform the experiment and provide a precise qualitative criterion on which decisions about respiratory infections can be evaluated. Not bound by any particular theory, it is believed that the use of marker combinations may increase the sensitivity and specificity of the assay.

[0062] In some embodiments, two multiplex real-time PCR assays are provided for the high-sensitivity detection of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae, and for the high-sensitivity detection of Streptococcus pneumoniae and Neisseria meningitidis, respectively. This specification discloses compositions and methods for multiplex real-time PCR assays that enable rapid detection of common bacterial pathogens that cause respiratory infections. In some embodiments, methods and reagents are provided that utilize a fluorescent sequence-specific hybridization probe to provide a rapid and inexpensive solution for quality control of DNA extraction and real-time PCR steps.

[0063] The disclosed method may include the steps of: subjecting DNA derived from a blood sample or culture suspected of containing the six pathogens described above to multiplex polymerase chain reaction amplification using two groups of five sets each of concentration-optimized primer pairs and probes; processing the reaction mixture under optimal thermal conditions; and detecting the amplified DNA target by monitoring the fluorescence signal of a hydrolysis (TaqMan®) probe in each cycle and interpreting the data at the end of the program to report the final result. Multiplex PCR primers and probes designed and screened using the primer design software Primer 3 and Beacon Designer are disclosed herein. The method presented herein achieves rapid and highly sensitive detection and discrimination of the respiratory pathogens described above.

[0064] The compositions and methods presented herein offer numerous advantages over currently available methods. Firstly, common pathogens in respiratory tract infections, such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, M. catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae, can be detected simultaneously with a single sample. Secondly, this specification presents gene targets optimized for high sensitivity and high inclusion: (a) Two genes, ctrA and sodC, used as targets for detecting Neisseria meningitidis in species-specific assays, combine the high sensitivity of ctrA with the high inclusion of sodC, enabling the methods disclosed herein to achieve superior performance; (b) lytA is used as a target for Streptococcus pneumoniae because it is superior to other targets such as commonly used ply, but this disclosure provides for better identification of Streptococcus pneumoniae than other... (c) The marker cpsA, characterized by the minute, is added; (d) In recent laboratory-based reference studies, the fucK target is used instead of the hpd gene to identify Haemophilus influenzae because it has good sensitivity for detecting Haemophilus influenzae and good discrimination from H. haemolyticus; and (e) the gltA gene is conserved in all three Klebsiella pneumoniae strains, called KpI, KpII, and KpIII, so the disclosed method can avoid the loss of detection of strains of significant clinical importance. Thirdly, the internal controls disclosed herein can mainly point to false negative results caused by malfunctions of PCR inhibitors, analyzers, or reagents, and the Ct value of IAC can be stable and unaffected by sample volume. Fourthly, the primer / probe combinations and multiplex real-time PCR methods presented herein can achieve high sensitivity, high inclusion, and high specificity, as supported by the examples. Furthermore, the disclosed method is rapid and easy to implement.

[0065] Oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to target gene regions or their complements in Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, amplification of the target gene region of an organism in a sample (e.g., a blood sample or a respiratory sample) may indicate the presence, absence, and / or level of the organism in the sample.

[0066] The target gene region may vary. In some embodiments, lytA is used as a marker for detecting Streptococcus pneumoniae. LytA, the gene for autotricin, is highly conserved within the species, and this assay has been shown to best isolate Streptococcus pneumoniae from genotypically similar species, S. mitis, S. olaris, and S. pseudopneumoniae. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding lytA within Streptococcus pneumoniae (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, the lytA gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Streptococcus pneumoniae in a sample. In some embodiments, primers and probes capable of specifically binding to the lytA gene region of Streptococcus pneumoniae are used in the detection of the presence, absence, and / or level of Streptococcus pneumoniae in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the lytA gene region within Streptococcus pneumoniae include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 1-15 presented in Table 1 and sequences selected from the group consisting of sequence numbers 1-15.

[0067] In some embodiments, cpsA is used as a marker for detecting Streptococcus pneumoniae. As a capsular biosynthesis gene, cpsA can distinguish Streptococcus pneumoniae from closely related Streptococcus viridans and other Streptococcus pneumoniae-like streptococci, such as S. pseudopneumoniae. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding cpsA in Streptococcus pneumoniae (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, the cpsA gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Streptococcus pneumoniae in a sample. In some embodiments, primers and probes that can specifically bind to the cpsA gene region of Streptococcus pneumoniae are used in the detection of the presence, absence, and / or level of Streptococcus pneumoniae in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the cpsA gene region within Streptococcus pneumoniae include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 16-30 and sequences selected from the group consisting of sequence numbers 16-30, as presented in Table 1.

[0068] In some embodiments, sodC is used as a marker for detecting Neisseria meningitidis. SodC, a Cu-Zn superoxide dismutase gene, is found in Neisseria meningitidis but not in other Neisseria species. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding sodC in Neisseria meningitidis (e.g., under standard nucleic acid amplification conditions, e.g., standard PCR conditions, and / or strict hybridization conditions). In some embodiments, the sodC gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Neisseria meningitidis in a sample. In some embodiments, primers and probes capable of specifically binding to the sodC gene region of Neisseria meningitidis are used in detecting the presence, absence, and / or level of Neisseria meningitidis in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the sodC gene region within Neisseria meningitidis include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 31-44 and sequences selected from the group consisting of sequence numbers 31-44, as presented in Table 1.

[0069] In some embodiments, ctrA is used as a marker for detecting Neisseria meningitidis. ctrA encodes an outer membrane protein-coding gene and is highly conserved in isolates that contribute to invasive Neisseria meningitidis infection. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding ctrA in Neisseria meningitidis (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, the ctrA gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Neisseria meningitidis in a sample. In some embodiments, primers and probes capable of specifically binding to the ctrA gene region of Neisseria meningitidis are used in the detection of the presence, absence, and / or level of Neisseria meningitidis in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the ctrA gene region within Neisseria meningitidis include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 45-59 and sequences selected from the group consisting of sequence numbers 45-59, as presented in Table 1.

[0070] In some embodiments, nuc is used as a marker for detecting Staphylococcus aureus. The heat-stable nuclease (nuc) has been successfully used to distinguish Staphylococcus aureus from other Staphylococcus species. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding nuc within Staphylococcus aureus (e.g., under standard nucleic acid amplification conditions, e.g., standard PCR conditions, and / or strict hybridization conditions). In some embodiments, the nuc gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Staphylococcus aureus in a sample. In some embodiments, primers and probes capable of specifically binding to the nuc gene region of Staphylococcus aureus are used in the detection of the presence, absence, and / or level of Staphylococcus aureus in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the nuc gene region within Staphylococcus aureus include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 75-87 and sequences selected from the group consisting of sequence numbers 75-87, as presented in Table 3.

[0071] In some embodiments, fucK is used as a marker for detecting Haemophilus influenzae. The fucus kinase gene (fucK) encodes an enzyme involved in fucose metabolism and is the most highly conserved of the seven housekeeping genes utilized in the MLST (multilocus sequence typing) scheme for Haemophilus influenzae. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding fucK in Haemophilus influenzae (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, fucK is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Haemophilus influenzae in a sample. In some embodiments, primers and probes that can specifically bind to the fucK gene region of Haemophilus influenzae are used in detecting the presence, absence, and / or level of Haemophilus influenzae in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the fucK gene region within Haemophilus influenzae include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 88-100 and sequences selected from the group consisting of sequence numbers 88-100, as presented in Table 3.

[0072] In some embodiments, copB is used as a marker for detecting M. catarrhalis. The gene target copB (outer membrane protein) is relatively conserved and present in any test isolate and can be used to detect M. catarrhalis. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding copB in M. catarrhalis (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, copB is used as a target gene for DNA amplification to detect the presence, absence, and / or level of M. catarrhalis in a sample. In some embodiments, primers and probes that can specifically bind to the copB gene region of M. catarrhalis are used in the detection of the presence, absence, and / or level of M. catarrhalis in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the copB gene region within M. catarrhalis include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 101-115 and sequences selected from the group consisting of sequence numbers 101-115, as presented in Table 3.

[0073] In some embodiments, gltA is used as a marker for detecting Klebsiella pneumoniae. gltA is present in all three Klebsiella pneumoniae strains, known as KpI, KpII (K. wariicola), and KpIII (K. quasi-pneumoniae). In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that can specifically hybridize to the gene region encoding gltA in Klebsiella pneumoniae (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions, and / or under strict hybridization conditions). In some embodiments, the gltA gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of Klebsiella pneumoniae in a sample. In some embodiments, primers and probes capable of specifically binding to the gltA gene region of Klebsiella pneumoniae are used in the detection of the presence, absence, and / or level of Klebsiella pneumoniae in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the glTA gene region within Klebsiella pneumoniae include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 116-129 and sequences selected from the group consisting of sequence numbers 116-129, as presented in Table 3.

[0074] In some embodiments, an internal amplification control (IAC) is provided. The IAC is a sequence known in the NCBI database that does not exhibit significant nucleotide identity to any sequence and can be selected as an internal control marker. This internal control is primarily used to indicate false negative results caused by malfunctions of PCR inhibitors, analyzers, or reagents. The IAC may be used in nucleic acid amplification assays disclosed herein to determine whether the test conditions are acceptable for amplification and / or detection of the target nucleic acid sequence. The IAC may be incorporated into the methods and compositions presented herein to verify negative results, identify potential inhibitory specimens, or facilitate the quantification of biomass in a sample, including but not limited to viruses, bacteria, and fungi. For diagnostic applications, the simultaneous amplification and detection of two different DNA sequences, e.g., a pathogenic bacterial target sequence and an IAC target sequence, enables the use of the IAC. Primers and probes presented herein that can hybridize with the IAC may be useful in verifying negative results and monitoring for specimens that inhibit the reaction. In some embodiments, the IAC is added to the test sample. While not intended to be bound to a specific mechanism of action, the presence of the IAC in the same reactant as the target sequence allows the amplification assay disclosed herein to detect the presence of reaction inhibitors and / or conditions that may indicate a false negative result. As used herein, a false negative result may indicate the non-detection of the target sequence, but such indication is due not to the absence of the target sequence in the sample, but to human error or reaction conditions, such as the absence of a critical reaction element, the presence of a reaction inhibitor, or an error in performing the assay. In some embodiments, the IAC sequence is designed so that its 3' or 5' end contains a sequence common to the target nucleic acid sequence. In some embodiments, the IAC sequence is designed so that its 3' and 5' ends do not contain sequences common to the target nucleic acid sequence. The IAC sequence may be designed to contain a nucleic acid sequence different from the target nucleic acid sequence being amplified, so that the detection of the IAC amplification product can be differentiated from the detection of the target sequence (or its unit replica sequence).In some embodiments, probes are provided that bind to the unit replication sequence of the IAC but not to the unit replication sequence of the target sequence. Examples of oligonucleotides capable of specifically hybridizing to the IAC include, but are not limited to, sequences exhibiting at least approximately 85% identity to sequence numbers 60-74 and 130-134 presented in Table 2, and sequences selected from the group consisting of sequence numbers 60-74 and 130-134.

[0075] The IAC may contain or be derived from a vector (e.g., pBluescript DNA). The IAC may contain or be derived from a gene (e.g., the HBB gene). The IAC may contain or be derived from a non-coding sequence (e.g., the non-coding portion of pBluescript DNA). The IAC may contain a sequence that exhibits at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any number or range between any two of these values) to one or more of the following sequences (SEQ ID NOs 135-139).

[0076] CAGATCGATATGGGTGCCGTTCGAGCAGTTTAGCCCTAAATCACCCTACCGGCAGACGTATGTCACATTCACCAGGGAGACGCTTGACATTGGATGCTGTTGTGCGCCCTCAACAATGTAACGAATGGCTGCTTCGTCTCG (SEQ ID NO: 135); GCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTT (SEQ ID NO: 136); AGTGCCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAATCAAAAGAATAGACCGAGATAGGGTTGAGT (SEQ ID NO: 137); GGATGAAGTTGGTGGTGAGGCCCTGGGCAGGTTGGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCATGTGGAGACAGAGAAGACTCTTGGGTTTCTGATAGGC (SEQ ID NO: 138); and ATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCAC (SEQ ID NO: 139).

[0077] In some embodiments, compositions and methods are provided in which one or more of the primer / probe combinations presented herein (e.g., E1, E2, E3, E4, E5, E6, and / or E7) are used in combination with an IAC containing a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to one or more of the sequence numbers 135-139.

[0078] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0079] [Table 2]

[0080] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4]

[0081] This specification also presents oligonucleotides (e.g., amplification primers or probes) containing one, two, three, four, or more mismatches or universal nucleotides compared to SEQ ID NOs: 1-139 or their complements, which are identical to SEQ ID NOs: 1-139 or their complements by at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any number or range between any two of these values). In some embodiments, the oligonucleotide comprises a sequence selected from SEQ ID NOs: 1-139. In some embodiments, the oligonucleotide comprises a sequence that is identical to a sequence selected from SEQ ID NOs: 1-139 by at least about 85%. In some embodiments, the oligonucleotide consists of a sequence selected from SEQ ID NOs: 1-139. In some embodiments, the oligonucleotide consists of a sequence that is at least about 85% identical to, or at least about 95% identical to, a sequence selected from SEQ ID NOs: 1 to 139.

[0082] In some embodiments, primer / probe combinations are provided. These primer / probe combinations may include, for example, a forward primer, a reverse primer, and a probe (e.g., A3-lytA-FP, A3-lytA-RP, and A3-lytA-probe in tandem). The compositions and methods presented herein may include one or more of the primer / probe combinations presented in Tables 1-3. For example, a method or composition may include a primer / probe combination with A3 (e.g., A3-lytA-FP, A3-lytA-RP, and A3-lytA-probe in tandem). Methods and compositions comprising two or more primer / probe combinations (e.g., multiplexing reactions) are disclosed herein. For example, a method or composition may include a combination of primers / probes according to A3, B3, C3, and D3 (e.g., A3-lytA-FP, A3-lytA-RP, A3-lytA-probe, B3-cpsA-FP, B3-cpsA-RP, B3-cpsA-probe, C3-sodC-FP, C3-sodC-RP, C3-sodC-probe, D3-ctrA-FP, D3-ctrA-RP, and D3-ctrA-probe in tandem).This specification refers to (1) combinations of one or more primers / probes that can specifically hybridize to the lytA gene or its complement sequence of Streptococcus pneumoniae (e.g., A1, A2, A3, A4 and / or A5); (2) combinations of one or more primers / probes that can specifically hybridize to the cpsA gene or its complement sequence of Streptococcus pneumoniae (e.g., B1, B2, B3, B4 and / or B5); (3) combinations of the sodC gene or its complement sequence of Neisseria meningitidis (4) A combination of one or more primers / probes that can specifically hybridize to a sequence (e.g., C1, C2, C3, C4, and / or C5); (5) A combination of one or more primers / probes that can specifically hybridize to the sequence of the ctrA gene of Neisseria meningitidis or its complement (e.g., D1, D2, D3, D4, and / or D5); (6) A combination of one or more primers / probes that can specifically hybridize to the sequence of an internal amplification control (IAC) or its complement. (6) A combination of primers / probes (e.g., E1, E2, E3, E4, E5, E6 and / or E7); (7) A combination of primers / probes (e.g., F1, F2, F3, F4 and / or F5) that can specifically hybridize to the nuc gene or its complement sequence of Staphylococcus aureus; (8) A combination of primers / probes (e.g., G1, G2, G3, Methods and compositions are disclosed comprising: (8) a combination of one or more primers / probes (e.g., H1, H2, H3, H4, and / or H5) capable of specifically hybridizing to the sequence of the copB gene or its complement of M. catarrhalis; and / or (9) a combination of one or more primers / probes (e.g., I1, I2, I3, I4, and / or I5) capable of specifically hybridizing to the sequence of the gltA gene or its complement of Klebsiella pneumoniae.This specification discloses methods and compositions comprising one or more of the primer / probe combinations presented in Table 4. This specification discloses methods and compositions comprising one or more of the primer / probe combinations presented in Table 5. This specification discloses methods and compositions comprising one or more of the primer / probe combinations presented in Table 6. This specification discloses methods and compositions comprising one or more of the primer / probe combinations presented in Table 7.

[0083] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]

[0084] [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] Table 5-7

[0085] Table 6-1 Table 6-2 Table 6-3 Table 6-4 Table 6-5 Table 6-6

[0086] Table 7-1 Table 7-2 Table 7-3 Table 7-4 Table 7-5 Table 7-6 Table 7-7

[0087] The nucleic acids presented herein can be in a variety of forms. For example, in some embodiments, the nucleic acids are dissolved in a solution, such as a buffer (alone or in combination with other various nucleic acids). In some embodiments, the nucleic acids are provided as salts, either alone or in combination with other isolated nucleic acids. In some embodiments, the nucleic acids are provided in a reconstituteable lyophilized form. For example, in some embodiments, the isolated nucleic acids disclosed herein may be provided alone in a lyophilized pellet or in a lyophilized pellet with other isolated nucleic acids. In some embodiments, the nucleic acids are provided immobilized on solid materials such as beads or membranes. In some embodiments, the nucleic acids are provided within host cells, for example, within a cell line containing plasmids or within a cell line containing stably incorporated sequences.

[0088] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the lytA gene or its complement sequence of Streptococcus pneumoniae. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the lytA gene or its complement sequence of Streptococcus pneumoniae. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the lytA gene of Streptococcus pneumoniae. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs: 1 to 15, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 15. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 15, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 15. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 15.

[0089] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the cpsA gene or its complement sequence of Streptococcus pneumoniae. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the cpsA gene or its complement sequence of Streptococcus pneumoniae. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the cpsA gene of Streptococcus pneumoniae. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs: 16-30, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 16-30. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 16 to 30, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 16 to 30. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 16 to 30. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 16 to 30.

[0090] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the sodC gene or its complement sequence of Neisseria meningitidis. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the sodC gene or its complement sequence of Neisseria meningitidis. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the sodC gene of Neisseria meningitidis. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs: 31-44, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 31-44. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 31 to 44, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 31 to 44. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 31 to 44. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 31 to 44.

[0091] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the crtA gene or its complement sequence of Neisseria meningitidis. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the crtA gene or its complement sequence of Neisseria meningitidis. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the crtA gene of Neisseria meningitidis. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs. 45-59, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs. 45-59. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 45 to 59, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 45 to 59. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 45 to 59. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 45 to 59.

[0092] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to an internal amplification control (IAC) or its complement sequence. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to an internal amplification control (IAC) or its complement sequence. In some embodiments, probes or primers with a length of about 100 nucleotides or less, capable of hybridizing to an internal amplification control (IAC), are provided. In some embodiments, the probes or primers include sequences selected from the group consisting of SEQ ID NOs. 60-74 and 130-134, or sequences exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to sequences selected from the group consisting of SEQ ID NOs. 60-74 and 130-134. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 60-74 and 130-134, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 60-74 and 130-134. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 60-74 and 130-134. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 60-74 and 130-134.

[0093] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the nuc gene or its complement sequence of Staphylococcus aureus. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the nuc gene or its complement sequence of Staphylococcus aureus. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the nuc gene of Staphylococcus aureus. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs. 75-87, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs. 75-87. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 75 to 87, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 75 to 87. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 75 to 87.

[0094] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the fucK gene or its complement sequence of Haemophilus influenzae. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the fucK gene or its complement sequence of Haemophilus influenzae. In some embodiments, probes or primers of about 100 nucleotides or less in length are provided that are capable of hybridizing to the fucK gene of Haemophilus influenzae. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs. 88-100, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs. 88-100. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 88 to 100, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs. 88 to 100. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs. 88 to 100.

[0095] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the sequence of the copB gene or its complement of M. catarrhalis. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the sequence of the copB gene or its complement of M. catarrhalis. In some embodiments, probes or primers of about 100 nucleotides or less in length are provided that are capable of hybridizing to the copB gene of M. catarrhalis. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs: 101-115, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 101-115. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 101 to 115, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 101 to 115. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 101 to 115. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 101 to 115.

[0096] In some embodiments, the composition, reaction mixture, and kit include one or more pairs of amplification primers capable of specifically hybridizing to the gltA gene or its complement sequence of Klebsiella pneumoniae. In some embodiments, the composition, reaction mixture, and kit include one or more probes capable of specifically hybridizing to the gltA gene or its complement sequence of Klebsiella pneumoniae. In some embodiments, probes or primers with a length of about 100 nucleotides or less are provided, capable of hybridizing to the gltA gene of Klebsiella pneumoniae. In some embodiments, the probes or primers include a sequence selected from the group consisting of SEQ ID NOs: 116-129, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 116-129. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 116 to 129, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 116 to 129. In some embodiments, the probe or primer includes a sequence selected from the group consisting of SEQ ID NOs: 116 to 129. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 116 to 129. In some embodiments, compositions are provided that include two or more oligonucleotide probes and / or primers from among those disclosed herein.

[0097] In some embodiments, the oligonucleotide probe may include a detection portion. For example, the oligonucleotide probes disclosed herein may include radiolabeling. Non-limiting examples of radiolabeling include: 3 H, 14 C, 32 P, and 35It contains S. In some embodiments, the oligonucleotide probe may include one or more non-radioactive detection markers or non-radioactive detection moieties, including but not limited to ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detection markers for use with probes that may allow for increased sensitivity of the method of the present invention include biotin and radionucleotides. Those skilled in the art will see that the choice of particular label determines how it is bound to the probe. For example, the oligonucleotide probe is labeled with one or more dyes such that a detectable change in fluorescence occurs upon hybridization with a template nucleic acid. For some applications, non-specific dyes may also be desired, but sequence-specific probes may provide more accurate measurements of amplification. One configuration of a sequence-specific probe may include one end of the probe tethered to a fluorophor and the other end of the probe tethered to a quencher. If the probe is not hybridized, the fluorophore may be quenched by the quenching agent, thereby preventing the fluorophore from fluorescing. If the probe is hybridized to a template nucleic acid sequence, it may be linearized, moving the fluorophore away from the quenching agent, thereby enabling the fluorophore to fluoresce. Another configuration of a sequence-specific probe may include a first probe tethered to a first fluorophore of a FRET pair and a second probe tethered to a second fluorophore of a FRET pair. The first and second probes may be configured to hybridize to sequences of the unit replication sequence that are within a sufficiently close range to allow energy transfer by FRET when hybridized to the same unit replication sequence.

[0098] In some embodiments, the probe is a TaqMan probe. A TaqMan probe may comprise a fluorophore and a quencher. The quencher molecule, when excited by a cycler light source via Förster resonance energy transfer (FRET), can quench the fluorescence emitted by the fluorophore. Quenching can inhibit any detection (e.g., fluorescence) signal as long as the fluorophore and the quencher are in close proximity. The TaqMan probes presented herein may be designed to anneal within the DNA region amplified by the primers presented herein. Without being bound by any particular theory, in some embodiments, as the PCR polymerase (e.g., Taq) extends the primer and synthesizes a nascent strand on a single-strand template, the 5'-3' exonuclease activity of the PCR polymerase degrades the probe annealed to the template. Probe degradation releases fluorophores from the probe, cleaving the portion adjacent to the quencher, thereby eliminating the quenching effect and enabling fluorescence of the fluorophores. Therefore, in some embodiments, the fluorescence detected in a quantitative PCR thermal cycler may be directly proportional to the amount of released fluorophores and DNA template present in the PCR.

[0099] In some embodiments, the sequence-specific probe comprises an oligonucleotide disclosed herein, conjugated to a fluorophore. In some embodiments, the probe is conjugated to two or more fluorophores. Examples of fluorophores include xanthene dyes, e.g., fluorescein isothiocyanate (FITC), 2-[ethylamino)-3-(ethylimino)-2-7-dimethyl-3H-xanthene-9-yl]benzoate ethyl ester monohydrochloride (R6G) (emitting response radiation in the wavelength range of about 500-560 nm), 1,1,3,3,3',3'-hexamethylindodicarbocyanine iodide (HIDC) (emitting response radiation in the wavelength range of about 600-660 nm), 6-carboxyfluorescein (commonly known by the abbreviations FAM and F), 6-carboxy-2',4',7',4,7-hexachloro Fluorescein dyes and rhodamine dyes such as fluorofluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G5 or G5), 6-carboxyrhodamine-6G (R6G6 or G6), and rhodamine 110; cyanine dyes, e.g., Cy3 dyes, Cy5 dyes, and Cy7 dyes; coumarins, e.g., umbelliferone; benzimide dyes, e.g., Hoechst 33258; Phenanthidine dyes, e.g., Texas Red; Ethidium dyes; Acridine dyes; Carbazole dyes; Phenoxazine dyes; Porphyrin dyes; Polymethine dyes, e.g., cyanine dyes such as Cy3 (emitting response radiation in the wavelength range of approximately 540-580 nm) and Cy5 (emitting response radiation in the wavelength range of approximately 640-680 nm); BODIPY dyes and quinoline dyes.The specific fluorophores of interest include pyrene, coumarin, diethylaminocoumarin, FAM, chlorotriazinylfluorescein, fluorescein, R110, eosin, JOE, R6G, HIDC, tetramethylrhodamine, TAMRA, Lissamine, ROX, naphthofluorescein, Texas Red, naphthofluorescein, Cy3 and Cy5, CAL fluor orange, and others. Other examples of fluorescein dyes include 6-carboxyfluorescein (6-FAM), 2',4',1,4-tetrachlorofluorescein (TET), 2',4',5',7',1,4-hexachlorofluorescein (HEX), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyrhodamine (JOE), 2'-chloro-5'-fluoro-7',8'-fusionphenyl-1,4-dichloro-6-carboxyfluorescein (NED), and 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC). The probe may contain SpC6 or its functional equivalents and derivatives. The probe may contain a spacer portion. The spacer portion may contain an alkyl group having at least 2 to about 12 carbon atoms. The probe may contain a spacer containing a non-basic unit. The probe may include a spacer selected from the group consisting of idSp, iSp9, iS18, iSpC3, iSpC6, iSpC12, or any combination thereof.

[0100] In some embodiments, the probe is conjugated to a quencher. The quencher absorbs electromagnetic radiation and dissipates it as heat, thus maintaining a dark color. Exemplary quenchers include Dabcyl, NFQs such as BHQ-1 or BHQ-2 (Biosearch), IOWA BLACK FQ (IDT), and IOWA BLACK RQ (IDT). In some embodiments, the quencher is selected to pair with the fluorophore to absorb the electromagnetic radiation emitted by the fluorophore. In the art, fluorophore / quencher pairs useful in the compositions and methods disclosed herein are well known and may be found, for example, in Marras, “Selection of Fluorophore and Quencher Pairs for Fluorescent Nucleic Acid Hybridization Probes,” available at www.molecular-beacons.org / download / marras,mmb06%28335%293.pdf, as described therein. Examples of quenching agents include, but are not limited to, dark quenchers, Black Hole Quencher® (BHQ®) (e.g., BHQ-0, BHQ-1, BHQ-2, BHQ-3), Qx1 quenchers, ATTO quenchers (e.g., ATTO 540Q, ATTO 580Q, and ATTO 612Q), dimethylaminoazobenzenesulfonic acid (Dabsyl), Iowa Black RQ, Iowa Black FQ, IRDye QC-1, QSY dyes (e.g., QSY 7, QSY 9, QSY 21), AbsoluteQuencher, Eclipse, and metal clusters such as gold nanoparticles. Examples of ATTO quenchers include, but are not limited to, ATTO 540Q, ATTO 580Q, and ATTO 612Q. Examples of Black Hole Quencher® (BHQ®) include, but are not limited to, BHQ-0 (493nm), BHQ-1 (534nm), BHQ-2 (579nm), and BHQ-3 (672nm).

[0101] In some embodiments, the detection label is an Alexa Fluor® dye (e.g., Alexa Fluor® 350, Alexa Fluor® 405, Alexa Fluor® 430, Alexa Fluor® 488, Alexa Fluor® 500, Alexa Fluor® 514, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 610, Alexa Fluor® 633, Alexa Fluor® 635, Alexa Fluor® 647, Alexa Fluor® 660, Alexa Fluor® 680, Alexa Fluor® 700, Alexa Fluor® 750, and Alexa Fluor® 790), or an ATTO dye (e.g., ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO 590, ATTO 594, ATTO Rhol3, ATTO 610, ATTO 620, ATTO Rhol4, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxal2, ATTO 665, ATTO 680, ATTO 700, ATTO DyFight dyes (e.g., Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, and Cy7).5) Fluorescent labels selected from FluoProbes dyes, SulfoCy dyes, Seta dyes, IRIS dyes, SeTau dyes, SRfluor dyes, Square dyes, fluorescein isothiocyanate (FITC), tetramethylrhodamine (TRITC), Texas Red, Oregon Green, Pacific Blue, Pacific Green, Pacific Orange, quantum dots, and tethering fluorescent proteins.

[0102] In some embodiments, a fluorophore is attached to the first end of the probe, and a quencher is attached to the second end of the probe. In some embodiments, the probe may contain two or more fluorophores. In some embodiments, the probe may contain two or more quenching moieties. In some embodiments, the probe may contain one or more quenching moieties and / or one or more fluorophores. The quenching moieties or fluorophores may be attached to any part of the probe (e.g., on the 5' end, on the 3' end, and / or in the middle of the probe). Any probe nucleotide may contain a fluorophore and / or a quenching moiety, such as iBHQ1dT. For example, with respect to the F1-nuc-probe (TTTCGTAAATGCACTTGCTTCAGGACCA; SEQ ID NO: 84), any of the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth "T" may include a fluorophore moiety or a quencher moiety (e.g., iBHQ1dT). The conjugate includes a covalent bond and may include at least one linker molecule positioned between the probe and the fluorophore or quencher. In some embodiments, the fluorophore is conjugated to the 5' end of the probe and the quencher is conjugated to the 3' end of the probe. In some embodiments, the fluorophore is conjugated to the 3' end of the probe and the quencher is conjugated to the 5' end of the probe. Examples of probes that can be used in quantitative nucleic acid amplification include molecular beacons, SCORPION® probes (Sigma), and TAQMAN® probes (Life Technologies). Other nucleic acid detection techniques useful in the embodiments disclosed herein include, but are not limited to, nanoparticle probe techniques (see Elghanian, et al. (1997) Science 277:1078-1081) and Amplifluor probe techniques (see U.S. Patents No. 5,866,366; No. 6,090,592; No. 6,117,635; and No. 6,117,986).

[0103] In some embodiments, compositions are provided for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the composition is at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of SEQ ID NOs: 1, 2, 3, 4, 5%, 96%, 97%, 98%, 99%, 100%, or any two of these values; at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity to any one of the sequences of SEQ ID NOs: 1, 2, 3, 4, 5%, 96%, 97%, 98%, 99%, 100%, or any two of these values; A pair of primers comprising a sequence exhibiting at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any number or range between any two of these values); a pair of primers capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein the pair of primers comprising the%); a pair of primers capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein the pair of primers comprising the sequence exhibiting at least approximately 85% identity At least one primer pair in which each primer within the primer pair contains a sequence that exhibits at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 31–39;The invention also includes at least one primer pair capable of hybridizing to the meningococcal crtA gene, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 45 to 54. The composition may include at least one control primer pair capable of hybridizing with an internal amplification control (IAC), wherein each primer in the at least one primer pair contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 60-69 and 130-132.

[0104] In some embodiments, at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae comprises a primer containing the sequence of SEQ ID NO: 1, 3, 5, 7, or 9, and a primer containing the sequence of SEQ ID NO: 2, 4, 6, 8, or 10; and at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae comprises a primer containing the sequence of SEQ ID NO: 16, 18, 20, 22, or 24, and a primer containing the sequence of SEQ ID NO: 17, 19, 21, 23, or 25. The following are included: at least one primer pair capable of hybridizing to the meningococcal sodC gene, comprising a primer containing the sequence of SEQ ID NO: 31, 33, 35, 36, or 38, and a primer containing the sequence of SEQ ID NO: 32, 34, 37, or 39; at least one primer pair capable of hybridizing to the meningococcal crtA gene, comprising a primer containing the sequence of SEQ ID NO: 45, 47, 49, 51, or 53, and a primer containing the sequence of SEQ ID NO: 46, 48, 50, 52, or 54. In some embodiments, at least one control primer pair capable of hybridizing to IAC, comprising a primer containing the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a primer containing the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

[0105] The composition may contain multiple oligonucleotide probes, in which case each of the multiple oligonucleotide probes contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. Each of the multiple oligonucleotide probes may contain a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. Each of the multiple oligonucleotide probes may consist of a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. At least one of the multiple probes may contain a fluorescently emitting portion and a fluorescently quenched portion.

[0106] In some embodiments, compositions are provided for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the composition comprises at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer in the at least one primer pair contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any two of these values) to any one of the sequences of SEQ ID NOs. Primer pair; at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, wherein each primer in the at least one primer pair contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence 88–95; M.At least one primer pair capable of hybridizing to the copB gene of Catarrhalis, wherein each primer in the at least one primer pair contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 101 to 110; and The present invention relates to at least one primer pair capable of hybridizing to the glTA gene of Klebsiella pneumoniae, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 116 to 124. The composition may include at least one pair of control primers capable of hybridizing with an internal amplification control (IAC), wherein each primer in the at least one pair of control primers contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to one of the sequences of sequence numbers 60-69 and 130-132.

[0107] In some embodiments, at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus comprises a primer containing the sequence of SEQ ID NO: 75, 77, 79, 81, or 83, and a primer containing the sequence of SEQ ID NO: 76, 78, 80, or 82; at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae comprises a primer containing the sequence of SEQ ID NO: 88, 90, 92, 93, or 94, and a primer containing the sequence of SEQ ID NO: 89, 91, or 95; M. Cataler At least one primer pair capable of hybridizing to the squirrel copB gene comprises a primer containing the sequence of SEQ ID NO: 101, 103, 105, 107, or 109, and a primer containing the sequence of SEQ ID NO: 102, 104, 106, 108, or 110; at least one primer pair capable of hybridizing to the Klebsiella pneumoniae gltA gene comprises a primer containing the sequence of SEQ ID NO: 116, 118, 120, or 122, and a primer containing the sequence of SEQ ID NO: 117, 119, 121, 123, or 124. In some embodiments, at least one control primer pair capable of hybridizing to IAC comprises a primer containing the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a primer containing the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

[0108] In some embodiments, a plurality of oligonucleotide probes are provided, each of which contains a sequence that exhibits at least about 85% identity (for example, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, each of the multiple oligonucleotide probes includes a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. In some embodiments, at least one of the multiple probes includes a fluorescent portion and a fluorescent quenching portion. Any probe described herein may include a fluorescent portion, a fluorescently quenched portion, or both.

[0109] As disclosed herein, the reaction mixture may comprise one or more of the primers disclosed herein, one or more of the probes disclosed herein (e.g., fluorophore-containing probes), or any combination thereof. In some embodiments, the reaction mixture comprises one or more of the primer and / or probe-containing compositions disclosed herein. The reaction mixture may also comprise a variety of further components. Examples of further components in the reaction mixture include, but are not limited to, template DNA, DNA polymerase (e.g., Taq DNA polymerase), deoxynucleotides (dNTPs), buffers, divalent cations, monovalent cations such as potassium ions, and any combination thereof. In some embodiments, the reaction mixture is a master mix for real-time PCR.

[0110] sample This specification discloses methods and compositions suitable for detecting bacterial respiratory pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae in a wide variety of samples. As used herein, “sample” may refer to any type of biological material taken from a subject suspected of having a respiratory infection, in a number of one or more cases. Samples may include, for example, body fluids, tissues, or cells. Samples may include biological material taken directly from the subject, cultured cells or tissues, or any fractions or products made from or derived from biological material. Samples may be purified, partially purified, unpurified, enriched, or amplified.

[0111] The sample may be a biological sample, such as a clinical sample. In some embodiments, the sample is taken from a biological source such as blood, vagina, urethra, penis, anus, pharynx, cervix, fermented culture medium, or cell culture. The sample may include, for example, bodily fluids and cells derived from blood samples and / or respiratory samples. Biological samples may be used (i) directly as obtained from the subject or source, or (ii) after pretreatment to alter the characteristics of the sample. Therefore, before use, the test sample may be pretreated by, for example, disrupting cells or viral particles, preparing liquids from solid materials, diluting mucus, filtering liquids, concentrating liquids, inactivating interfering components, adding reagents, or purifying nucleic acids. Thus, as used herein, “biological sample” includes nucleic acids (DNA, RNA, or total nucleic acids) extracted from clinical or biological specimens. Sample preparation may also include a step of using a solution containing buffers, salts, surfactants, etc., used to prepare the sample for analysis. In some embodiments, the sample is processed before molecular testing. In some embodiments, the sample is analyzed directly and is not pre-treated before testing. The sample may be, for example, a blood sample or a respiratory sample. In some embodiments, the sample is a blood sample or a respiratory sample derived from a patient with clinical symptoms of a respiratory tract infection.

[0112] Blood or respiratory samples are often infected with multiple organisms. The disclosed primers and probes are resistant to mixed infections of the blood matrix or respiratory matrix.

[0113] In some embodiments, the test sample is processed before carrying out the method disclosed herein. For example, in some embodiments, the sample may be isolated, concentrated, or subjected to a variety of other processing steps before carrying out the method disclosed herein. For example, in some embodiments, the sample may be processed so that nucleic acids are isolated from the sample before the step of contacting the sample with the oligonucleotide disclosed herein. In some embodiments, the method disclosed herein is carried out on the sample without culturing the sample in vitro. In some embodiments, the method disclosed herein is carried out on the sample without isolating nucleic acids from the sample before the step of contacting the sample with the oligonucleotide disclosed herein.

[0114] The sample may contain one or more types of nucleic acids (e.g., multiple types of nucleic acids). As used herein, the term “multiple” may refer to two or more types. Therefore, in some embodiments, the sample contains two or more types of nucleic acids (e.g., gDNA, mRNA) (e.g., three or more, five or more, ten or more, twenty or more, fifty or more, 100 or more, 500 or more, 1,000 or more, or 5,000 or more). The disclosed method can be used as an extremely sensitive method for detecting a target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) present in a sample (e.g., in a complex mixture of nucleic acids, such as gDNA). In some embodiments, the sample includes five or more nucleic acids with distinct sequences (for example, 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 1,000 or more, or 5,000 or more nucleic acids). In some embodiments, the sample includes 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 10 3Species or more, 5 x 10 3 10 species or more 4 Species or more, 5 x 10 4 10 species or more 5 Species or more, 5 x 10 5 10 species or more 6 Species or more, 5 x 10 6 species or more, or 10 7 Contains one or more species of nucleic acids.

[0115] In some embodiments, the samples are 10-20 types, 20-50 types, 50-100 types, 100-500 types, and 500-100 types. 3 seeds, 10 3 ~5×10 3 Seeds, 5x10 3 ~10 4 seeds, 10 4 ~5×10 4 Seeds, 5x10 4 ~10 5 seeds, 10 5 ~5×10 5 Seeds, 5x10 5 ~10 6 seeds, 10 6 ~5×10 6 Seeds, or 5 x 10 6 ~10 7 seeds, or 10 7 It contains nucleic acids of more than one species. In some embodiments, the sample contains 5 to 10 7 Nucleic acids of different species (for example, those with sequences that differ from each other) (for example, 5-10 6 , 5~10 5 , 5-50,000, 5-30,000, 10-10 6 , 10~10 5 , 10-50,000, 10-30,000, 20-10 6 , 20~10 5 The sample includes 20 to 50,000 nucleic acids, or 20 to 30,000 nucleic acids, or a number or range of nucleic acids between any two of these values. In some embodiments, the sample includes 20 or more nucleic acids with distinct sequences.

[0116] As used herein, the term “sample” may mean any sample containing nucleic acids (e.g., for determining whether a target sequence is present in a population of nucleic acids). Samples may originate from any source, for example, a sample may be a synthetic combination of purified nucleic acids; a sample may be cell lysates, DNA-enriched cell lysates, or nucleic acids isolated and / or purified from cell lysates. Samples may originate from a patient (e.g., for diagnostic purposes). Samples may originate from permeabilized cells. Samples may originate from cross-linked cells. Samples may be cells in a tissue section. Samples may originate from tissue prepared by cross-linking followed by delipidation and correction to obtain a uniform refractive index.

[0117] The "sample" may include a target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) and several types of non-target nucleic acids. In some embodiments, the target nucleic acid may be present in the sample in the following quantities: one copy per 10 non-target nucleic acids, one copy per 20 non-target nucleic acids, one copy per 25 non-target nucleic acids, one copy per 50 non-target nucleic acids, one copy per 100 non-target nucleic acids, one copy per 500 non-target nucleic acids, and 10 3 One copy per non-target nucleic acid of a species, 5 × 10 3 One copy per non-target nucleic acid of each species, 10 4 One copy per non-target nucleic acid of a species, 5 × 10 4 One copy per non-target nucleic acid of each species, 10 5 One copy per non-target nucleic acid of a species, 5 × 10 5 One copy per non-target nucleic acid of each species, 10 6 One copy per non-target nucleic acid of each species, 10 6The target nucleic acid is present in the sample in a number of copies less than one per nontarget nucleic acid species, or in a number or range between any two of these values. In some embodiments, the target nucleic acid is present in the sample in the following order: 1 copy per 10 nontarget nucleic acids to 1 copy per 20 nontarget nucleic acids, 1 copy per 20 nontarget nucleic acids to 1 copy per 50 nontarget nucleic acids, 1 copy per 50 nontarget nucleic acids to 1 copy per 100 nontarget nucleic acids, 1 copy per 100 nontarget nucleic acids to 1 copy per 500 nontarget nucleic acids, and 1 copy per 500 nontarget nucleic acids to 10 3 One copy per non-target nucleic acid of each species, 10 3 One copy per non-target nucleic acid of a species ~5 × 10 3 One copy per non-target nucleic acid of a species, 5 × 10 3 One copy per non-target nucleic acid of a species ~ 10 4 One copy per non-target nucleic acid of each species, 10 4 One copy per non-target nucleic acid of a species ~ 10 5 One copy per non-target nucleic acid of each species, 10 5 One copy per non-target nucleic acid of a species ~ 10 6 One copy per non-target nucleic acid species, or 10 6 One copy per non-target nucleic acid of a species ~ 10 7 There is one copy per non-target nucleic acid of a species, or a number or range of copies between any two of these values.

[0118] Appropriate samples include, but are not limited to, saliva samples, blood samples, serum samples, plasma samples, urine samples, aspiration samples, and biopsy samples. Therefore, in relation to a patient, the term “sample” encompasses blood and other biologically derived liquid samples, biopsy specimens or tissue cultures, or solid tissue samples such as cells and their progeny derived therefrom. The definition also includes samples that have been manipulated in any way after their procurement, such as by processing with reagents; washing; or enrichment for a particular cell population, such as cancer cells. The definition also includes samples enriched for a particular type of molecule, such as nucleic acids. The term “sample” encompasses biological samples such as blood, plasma, serum, aspiration, cerebrospinal fluid (CSF), and also includes tissues obtained by surgical excision, tissues obtained by biopsy, cells in culture, cell supernatant, cell lysates, tissue samples, organs, bone marrow, etc. "Biological samples" include bodily fluids derived from these (e.g., cancerous cells, infected cells, etc.), and samples containing nucleic acids obtained from such cells (e.g., cell lysates or other cell extracts containing nucleic acids).

[0119] Suitable samples for use in the methods disclosed herein include all common biological samples obtained from living organisms or parts thereof, such as plants, animals, and bacteria. In certain embodiments, biological samples are obtained from animal subjects, such as human subjects. Biological samples are, without limitation, any solid or fluid samples obtained from, or excreted or secreted by, any living organisms, including, in particular, single-celled organisms such as bacteria, yeasts, protozoa, and amoebas (including plants or animals, etc., which include samples from human subjects or human patients that are healthy, or that are suffering from a condition or disease to be diagnosed or sought, such as infection by pathogenic microorganisms such as pathogenic bacteria or viruses, and which appear healthy). For example, a biological sample may be, for instance, a bodily fluid obtained from blood, plasma, serum, urine, feces, sputum, mucus, lymphatic fluid, synovial fluid, bile, ascites, pleural fluid, serumoma, saliva, cerebrospinal fluid, aqueous humor, or vitreous fluid, or any secretion, exudate, or fluid (e.g., abscess or any other site of infection or inflammation), or a bodily fluid obtained from a joint (e.g., a normal joint or a joint affected by a disease such as rheumatoid arthritis, osteoarthritis, gout, or septic arthritis), or a skin swab or mucosal surface.

[0120] The sample may also be a sample obtained from any organ or tissue (including biopsy specimens such as tumor biopsies or autopsy specimens), and may include cells (whether primary or cultured) or culture media conditioned with any cell, tissue, or organ. Exemplary samples, without limitation, include cells, cell lysates, blood smears, cell centrifugation preparations, cytological smears, body fluids (e.g., blood, plasma, serum, saliva, sputum, urine, bronchoalveolar lavage fluid, semen, etc.), tissue biopsies (e.g., tumor biopsies), fine-needle aspirations, and / or tissue sections (e.g., cryostat tissue sections and / or paraffin-embedded tissue sections). In other examples, the sample may include circulating tumor cells (which may be identified by cell surface markers). In certain cases, samples may be used directly (e.g., freshly collected or frozen) or processed before use, for example, by fixation (e.g., using formalin) and / or embedding in wax (e.g., formalin-fixed paraffin-embedded (FFPE) tissue samples). Any method of obtaining tissue from a subject is available, and the choice of method used will depend on a variety of factors, such as the type of tissue, the age of the subject, or the procedures available to the laboratory personnel. Standard techniques for collecting such samples are available in the art. In some embodiments, the sample may be an environmental sample such as water or soil, or a surface such as an industrial surface or a medical surface. To increase sensitivity in the embodiments disclosed herein, in certain exemplary embodiments, the assay and method may be tested on a crude sample, and the target molecule to be detected may be tested on a sample that has not been further fractionated or purified from the sample.

[0121] Sample extraction In sample extraction, cells are lysed by mechanical shearing with glass beads to lyse the target organism, as described in U.S. Patent No. 7,494,771, which is incorporated herein by reference in its entirety. As disclosed in International Publication No. WO03 / 008636, such general cell lysis methods are efficient for a wide variety of target organisms and sample matrices. Other lysis methods exist that are specifically designed to target certain species or groups of organisms, or that utilize specific enzymatic or chemical activity. For example, ACP enzymes are commonly used to lyse Gram-positive bacteria (Ezaki et al., J. Clin. Microbiol., 16(5):844-846 (1982); Paule et al., J. Mol. Diagn., 6(3):191-196 (2004); U.S. Patent No. 3,649,454; all of which are incorporated herein by reference in their entirety) and Mycobacteria (U.S. Patent No. 5,185,242, incorporated herein by reference in its entirety), but are generally considered less effective in lysing Gram-negative species such as Escherichia coli and Pseudomonas aeruginosa (U.S. Patent No. 3,649,454, incorporated herein by reference in its entirety).

[0122] Nucleic acid testing The methods described herein may include, for example, nucleic acid testing. For example, the testing may include testing for a target nucleic acid sequence in a sample. In the embodiments disclosed herein, a variety of nucleic acid tests may be used, including, but not limited to, tests involving nucleic acid amplification. The target nucleic acid (e.g., gDNA, mRNA) may be single-stranded or double-stranded. The source of the target nucleic acid may be any source (e.g., any sample). In some embodiments, the target nucleic acid is bacterial nucleic acid (e.g., bacterial genomic DNA (gDNA) or mRNA). Thus, the compositions and methods presented herein may be used to detect the presence of bacterial nucleic acid in a nucleic acid population (e.g., in a sample).

[0123] This specification presents compositions and methods for detecting a target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) in a sample, wherein the target nucleic acid can be detected with high sensitivity. In some embodiments, the compositions and methods presented herein may be used to detect a target nucleic acid present in a sample containing multiple types of nucleic acids (including a target nucleic acid and multiple types of non-target nucleic acids), in which case the target nucleic acid is 10 7 One or more copies per non-target nucleic acid species (e.g., 10) 6 One or more copies per non-target nucleic acid of a species, 10 5 One or more copies per non-target nucleic acid of a species, 10 4 One or more copies per non-target nucleic acid of a species, 10 3 One or more copies per non-target nucleic acid of a species, 10 2 (One or more copies per species of non-target nucleic acid, one or more copies per 50 species of non-target nucleic acids, one or more copies per 20 species of non-target nucleic acids, one or more copies per 10 species of non-target nucleic acids, or one or more copies per 5 species of non-target nucleic acids). In some embodiments, the disclosed method may be used to detect a target nucleic acid present in a sample containing multiple species of nucleic acids (including a target nucleic acid and multiple species of non-target nucleic acids), in which case the target nucleic acid is 10 18 One or more copies per non-target nucleic acid species (e.g., 10) 15 One or more copies per non-target nucleic acid of a species, 10 12 One or more copies per non-target nucleic acid of a species, 10 9 One or more copies per non-target nucleic acid of a species, 10 6 One or more copies per non-target nucleic acid of a species, 10 5 One or more copies per non-target nucleic acid of a species, 10 4 One or more copies per non-target nucleic acid of a species, 10 3 One or more copies per non-target nucleic acid of a species, 10 2They exist as one or more copies per species of nontarget nucleic acid, one or more copies per 50 species of nontarget nucleic acids, one or more copies per 20 species of nontarget nucleic acids, one or more copies per 10 species of nontarget nucleic acids, or one or more copies per 5 species of nontarget nucleic acids.

[0124] In some embodiments, the detection threshold for a method for detecting a disclosed target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) in a sample is 10 nM or less. As used herein, the term “detection threshold” may refer to the minimum amount of target nucleic acid that must be present in the sample for detection to occur. Thus, as stated in exemplary examples, if the detection threshold is 10 nM, a signal may be detected if the target nucleic acid is present in the sample at a concentration of 10 nM or greater. In some embodiments, the detection threshold (for detecting the target nucleic acid in the disclosed method) is in the range of 500 fM to 1 nM (e.g., 500 fM to 500 pM, 500 fM to 200 pM, 500 fM to 100 pM, 500 fM to 10 pM, 500 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or any number or range between any two of these values) (where concentration refers to the threshold concentration of the target nucleic acid at which the target nucleic acid can be detected). In some embodiments, the disclosed method has a detection threshold in the range of 800 fM to 100 pM. In some embodiments, the disclosed method has a detection threshold in the range of 1 pM to 10 pM. In some embodiments, the disclosed method has a detection threshold in the range of 10 fM to 500 fM, for example, 10 fM to 50 fM, 50 fM to 100 fM, 100 fM to 250 fM, or 250 fM to 500 fM, or a number or range between any two of these values.

[0125] In some embodiments, the minimum concentration at which the target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) can be detected in a sample is in the range of 500 fM to 1 nM (e.g., 500 fM to 500 pM, 500 fM to 200 pM, 500 fM to 100 pM, 500 fM to 10 pM, 500 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or any number or range between any two of these values). In some embodiments, the minimum detectable concentration of the target nucleic acid in the sample is in the range of 800 fM to 100 pM. In some embodiments, the minimum detectable concentration of the target nucleic acid in the sample is in the range of 1 pM to 10 pM.

[0126] In some embodiments, the detection threshold (for detecting the target nucleic acid in the disclosed method) is 1aM to 1nM (e.g., 1aM to 500pM, 1aM to 200pM, 1aM to 100pM, 1aM to 10pM, 1aM to 1pM, 100aM to 1nM, 100aM to 500pM, 100aM to 200pM, 100aM to 100pM, 100aM to 10pM, 100aM to 1pM) , 250aM~1nM, 250aM~500pM, 250aM~200pM, 250aM~100pM, 250aM~10pM, 250aM~1pM, 500aM~1nM, 500aM ~500pM, 500aM~200pM, 500aM~100pM, 500aM~10pM, 500aM~1pM, 750aM~1nM, 750aM~500pM, 750aM~200p M, 750aM~100pM, 750aM~10pM, 750aM~1pM, 1fM~1nM, 1fM~500pM, 1fM~200pM, 1fM~100pM, 1fM~10pM, 1 fM~1pM, 500fM~500pM, 500fM~200pM, 500fM~100pM, 500fM~10pM, 500fM~1pM, 800fM~1nM, 800fM~500p The detection threshold is in the range of M, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 10 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or any number or range between any two of these values) (where the concentration refers to the threshold concentration of the target nucleic acid at which the target nucleic acid can be detected). In some embodiments, the disclosed method has a detection threshold in the range of 1 aM to 800 aM. In some embodiments, the disclosed method has a detection threshold in the range of 50 aM to 1 pM. In some embodiments, the disclosed method has a detection threshold in the range of 50 aM to 500 fM.

[0127] In some embodiments, the minimum concentration at which the target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) can be detected in the sample is 1 aM to 1 nM (e.g., 1 aM to 500 pM, 1 aM to 200 pM, 1 aM to 100 pM, 1 aM to 10 pM, 1 aM to 1 pM, 100 aM to 1 nM, 100 aM to 500 pM, 100 aM to 200 pM, 100 aM to 100 pM, 100 a M~10pM, 100aM~1pM, 250aM~1nM, 250aM~500pM, 250aM~200pM, 250aM~100pM, 250aM~10pM, 250aM~ 1pM, 500aM~1nM, 500aM~500pM, 500aM~200pM, 500aM~100pM, 500aM~10pM, 500aM~1pM, 750aM~1nM, 750aM~500pM, 750aM~200pM, 750aM~100pM, 750aM~10pM, 750aM~1pM, 1fM~1nM, 1fM~500pM, 1fM~2 00pM, 1fM~100pM, 1fM~10pM, 1fM~1pM, 500fM~500pM, 500fM~200pM, 500fM~100pM, 500fM~10pM, 50 The range is 0 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 10 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or any number or range between any two of these values. In some embodiments, the minimum concentration of the target nucleic acid that can be detected in the sample is in the range of 1 aM to 500 pM. In some embodiments, the minimum concentration of the target nucleic acid that can be detected in the sample is in the range of 100 aM to 500 pM. In some embodiments, the composition or method presented herein exhibits detection sensitivity in at-moles (aM). In some embodiments, the composition or method exhibits detection sensitivity in femtomoles (fM). In some embodiments, the composition or method in question exhibits detection sensitivity in the picomolar (pM) range. In some embodiments, the composition or method in question exhibits detection sensitivity in the nanomolar (nM) range.

[0128] As used herein, nucleic acid amplification may refer to any known procedure for obtaining multiple copies of a target nucleic acid sequence or its complement or fragment thereof using sequence-specific methods. Examples of known amplification methods include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand substitution amplification (SDA) (e.g., multiple substitution amplification (MDA)), replicase-mediated amplification, immuno-amplification, nucleic acid sequence-based amplification (NASBA), self-persistent sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA).For example, Mullis, "Process for Amplifying, Detecting, and / or Cloning Nucleic Acid Sequences," U.S. Patent No. 4,683,195; Walker, "Strand Displacement Amplification," U.S. Patent No. 5,455,166; Dean et al., "Multiple displacement amplification," U.S. Patent No. 6,977,148; Notomi et al., "Process for Synthesizing Nucleic Acid," U.S. Patent No. 6,410,278; Landegren et al., U.S. Patent No. 4,988,617, "Method of detecting a nucleotide change in nucleic acids"; Birkenmeyer, "Amplification of Target Nucleic Acids Using Gap Filling Ligase Chain Reaction," U.S. Patent No. 5,427,930; Cashman, "Blocked-Polymerase Polynucleotide Immunoassay Method and Kit," U.S. Patent No. 5,849,478; Kacian et al., "Nucleic Acid Sequence Amplification" See "Methods," U.S. Patent No. 5,399,491; Malek et al., "Enhanced Nucleic Acid Amplification Process," U.S. Patent No. 5,130,238; Lizardi et al., BioTechnology, 6:1197 (1988); Lizardi et al., U.S. Patent No. 5,854,033, "Rolling circle replication reporter systems." In some embodiments, two or more of the nucleic acid amplification methods described above may be performed sequentially, for example.

[0129] For example, LCR amplification uses at least four distinct oligonucleotides to amplify the target and its complementary strand by employing hybridization, ligation, and denaturation over multiple cycles (as described, e.g., in European Patent No. 0320308). SDA is amplified by amplification in a series of primer extension and strand substitution steps, following the use of a primer containing a recognition site for a restriction endonuclease that nicks one strand of a hemi-modified DNA double helix containing the target sequence (as described, e.g., in U.S. Patent No. 5,422,252).

[0130] PCR is a well-known method in the art for amplifying nucleic acids. PCR involves the amplification of a target sequence using two or more extendable sequence-specific oligonucleotide primers flanking the target sequence. A nucleic acid containing the target sequence of interest is subjected to a multi-round thermal cycling program (denaturation, annealing, and extension) in the presence of primers, a thermally stable DNA polymerase (e.g., Taq polymerase), and various dNTPs, resulting in amplification of the target sequence. PCR uses a multi-round primer extension reaction in which complementary strands of a specified region of the DNA molecule are simultaneously synthesized by the thermally stable DNA polymerase. At the end of each cycle, each of the newly synthesized DNA molecules acts as a template for the next cycle. During the iteration of these reaction rounds, the number of newly synthesized DNA strands increases exponentially, so that the initial template DNA is replicated thousands or millions of times after 20 to 30 reaction cycles. Methods for performing different types and techniques of PCR are fully described in the literature, for example, in “PCR Primer: A Laboratory Manual” Dieffenbach and Dveksler, eds. Cold Spring Harbor Laboratory Press, 1995, the contents of which are incorporated herein by reference in their entirety, as well as in patents (e.g., U.S. Nos. 4,683,195, 4,683,202, and 4,800,159), and in academic publications (e.g., Mullis et al. 1987, Methods in Enzymology, 155:335-350), by Mullis et al.

[0131] PCR can yield double-stranded amplification products suitable for post-amplification processing. If desired, the amplification products may be detected by visualization with agarose gel electrophoresis, by enzyme immunoassay formats using probe-based colorimetric detection, by fluorescence emission techniques, or by other detection methods known to those skilled in the art.

[0132] A wide variety of PCR methods are described in numerous sources, such as Ausubel et al. (eds.), Current Protocols in Molecular Biology, Section 15, John Wiley & Sons, Inc., New York (1994). Examples of PCR methods include, but are not limited to, real-time PCR, endpoint PCR, AFLP-PCR (amplified fragment length polymorphism PCR), Alu-PCR, asymmetric PCR, colony PCR, DD-PCR, denaturing PCR, hot-start PCR, in situ PCR, inverse PCR, long-chain PCR, multiplex PCR, nested PCR, PCR-ELISA, PCR-RFLP, PCR-SSCP (PCR-single strand conformation polymorphism), quantitative competitive PCR (QC-PCR), RACE-PCR (rapid amplification of cDNA ends-PCR), RAPD-PCR (Random Amplification of Polymorphic DNA-PCR), real-time PCR, Rep-PCR (Repetitive extragenic palindromic-PCR), reverse transcriptase PCR (RT-PCR), TAIL-PCR, touchdown PCR, and vectorette PCR.

[0133] Real-time PCR, also known as quantitative real-time polymerase chain reaction (QRT-PCR), can be used to simultaneously quantify and amplify specific portions of a given nucleic acid molecule. PCR can be used to determine whether a specific sequence is present in a sample; and, if present, to determine the copy number of the present sequence. The term "real-time" may refer to periodic monitoring during PCR. Certain systems, such as the ABI 7700 Sequence Detection System and ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, Calif), perform monitoring at predetermined or user-defined points between each thermal cycle. Real-time analysis with PCR using fluorescence resonance energy transfer (FRET) probes measures the change in the fluorescent dye signal between cycles, preferably after subtracting any internal control signals. The real-time procedure follows the general pattern of PCR, but the nucleic acid is quantified after each amplification round. Two examples of quantitative methods are the use of a fluorescent dye inserted into double-stranded DNA (e.g., SYBR Green) and a modified DNA oligonucleotide probe that fluoresces when hybridized with complementary DNA. The insertant emits relatively low fluorescence when unbound and relatively high fluorescence when bound to double-stranded nucleic acid. Thus, the insertant can be used to monitor the accumulation of double-stranded nucleic acid during nucleic acid amplification reactions. Examples of such nonspecific dyes useful in the embodiments disclosed herein include insertants such as SYBRGreenI (Molecular Probes), propidium iodide, and ethidium bromide.

[0134] Blood or respiratory samples are often infected with multiple organisms. The disclosed primers and probes are resistant to mixed infections of blood and respiratory matrices. For specific target sequences, primers, and probes, the methods and compositions disclosed herein can be used to detect the presence / absence or level of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and / or Klebsiella pneumoniae in a sample with high sensitivity, high specificity, and high accuracy. The primers disclosed herein provide an assay panel for detecting bacterial respiratory pathogens and can be paired with further PCR systems using homogeneous chemical reaction profiles and thermal PCR profiles to improve the sensitivity and robustness of the overall assay.

[0135] In some embodiments, multiplex PCR is performed, for example, by direct or indirect means, to amplify one or more species from among Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella (Branhamella) catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae, and to detect their presence or absence, enabling the diagnosis of respiratory tract infection using one or two tests.

[0136] Accordingly, some embodiments for detecting and / or identifying Streptococcus pneumoniae and Neisseria meningitidis in a sample include the steps of: preparing a test sample; and contacting the sample with oligonucleotide primers capable of specifically hybridizing and amplifying (1) the lytA gene of Streptococcus pneumoniae, (2) the cpsA gene of Streptococcus pneumoniae, (3) the sodC gene of Neisseria meningitidis, and (4) the crtA gene of Neisseria meningitidis, under standard nucleic acid amplification conditions and / or strict hybridization conditions, with oligonucleotide probes capable of specifically hybridizing (1) the lytA gene of Streptococcus pneumoniae, (2) the cpsA gene of Streptococcus pneumoniae, (3) the sodC gene of Neisseria meningitidis, and (4) the crtA gene of Neisseria meningitidis. Some embodiments for detecting and / or identifying Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample include the steps of: preparing a test sample; and contacting the sample with oligonucleotide primers capable of specifically hybridizing and amplifying (1) the nuc gene of Staphylococcus aureus, (2) the fucK gene of Haemophilus influenzae, (3) the copB gene of M. catarrhalis, and (4) the gltA gene of Klebsiella pneumoniae, under standard nucleic acid amplification conditions and / or strict hybridization conditions, with oligonucleotide probes capable of specifically hybridizing (1) the nuc gene of Staphylococcus aureus, (2) the fucK gene of Haemophilus influenzae, (3) the copB gene of M. catarrhalis, and (4) the gltA gene of Klebsiella pneumoniae. As described herein, the sample may be brought into contact with all of the primers and probes at once, or it may be brought into contact with some of the primers and probes first, and then with the rest of the primers and probes.

[0137] Oligonucleotide probes may be, for example, between approximately 10 and 45 nucleotides in length and may include a detection portion (e.g., a signal portion, a detection label). In some embodiments, the contact step is performed under conditions that allow for specific hybridization of the primer to the corresponding target gene region if the target organism is present in the sample. The presence and / or amount of probe specifically bound to the corresponding target gene region (if present in the test sample) can be determined, and the bound probe indicates the presence of the corresponding target organism in the sample. In some embodiments, the amount of bound probe is used to determine the amount of the corresponding target organism in the sample.

[0138] The determination step, after the contact step, can be achieved using any method known to those skilled in the art, including but not limited to in situ hybridization. Detection of the hybrid double helix (i.e., by a probe specifically bound to the target gene region) can be performed by a number of methods. Typically, the hybridized double helix is ​​separated from the non-hybridized nucleic acid, and then the label bound to the double helix is ​​detected. Such labels refer to radioactive tags or labels, fluorescent tags or labels, biological tags or labels, or enzyme tags or labels, which are standard in the art. The labels may be conjugated to oligonucleotide probes or to nucleic acids derived from biological samples. Those skilled in the art will understand that a washing step may be used to wash away excess sample / target nucleic acid or oligonucleotide probe (and, where applicable, non-bound conjugates). Furthermore, standard heterologous assay formats are suitable for detecting hybrids using labels present on oligonucleotide primers and probes. The step of determining the presence or amount of one or more unit replica sequences may include contacting the unit replica sequences with multiple oligonucleotide probes. At least one of the multiple oligonucleotide probes includes a fluorescent portion and a fluorescent quenching portion. In some embodiments, the step of determining the presence or amount of one or more unit replica sequences includes, for example, measuring a detection signal, such as a detection signal from the probes.

[0139] In some embodiments, the step of determining the presence or amount of one or more unit replication sequences may include, for example, measuring a detection signal, such as a detection signal from a probe (e.g., after the probe has been cleaved by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)). In some embodiments, the measurement may be quantitative in the sense that, for example, the amount of the detected signal can be used to determine the amount of target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) present in the sample. In some embodiments, the measurement may be qualitative in the sense that, for example, the presence or absence of a detection signal can indicate the presence or absence of target DNA (e.g., a virus, SNP, etc.). In some embodiments, there will be no detection signal (e.g., above a given threshold level) as long as the target DNA (e.g., a virus, SNP, etc.) is not present above a certain threshold concentration. In some embodiments, the disclosed method may be used to determine the amount of a target nucleic acid (e.g., the nuc gene of Staphylococcus aureus) in a sample (e.g., a sample comprising a target nucleic acid and several non-target nucleic acids). Determining the amount of the target nucleic acid in a sample may include comparing the amount of detection signal generated from the test sample with the amount of detection signal generated from a reference sample. Determining the amount of the target nucleic acid in a sample may include measuring the detection signal to generate a test measurement; measuring the detection signal provided by the reference sample to generate a reference measurement; and comparing the test measurement with the reference measurement to determine the amount of the target nucleic acid present in the sample. Determining the amount of the target nucleic acid in a sample may be used to derive the presence and / or amount of organisms containing the target nucleic acid in the sample.

[0140] In some embodiments, the detection signal to be measured is provided by a fluorescent dye pair of the probe. For example, in some embodiments, the disclosed method includes the step of contacting a unit replica array with a probe containing a fluorescence resonance energy transfer (FRET) pair or a quencher / fluorophore pair, or both. In some embodiments, the disclosed method includes the step of contacting a unit replica array with a probe containing a FRET pair. In some embodiments, the disclosed method includes the step of contacting a unit replica array with a probe containing a fluorophore / quencher pair. A fluorescent dye pair includes a FRET pair or a quencher / fluorophore pair. In both embodiments of a FRET pair and a quencher / fluorophore pair, the emission spectrum of one of the dyes overlaps with the absorption spectrum region of the other dye in the pair. As used herein, the term “fluorescent dye pair” is a general term used to encompass both “fluorescence resonance energy transfer (FRET) pairs” and “quencher / fluorophore pairs,” which are discussed in more detail below. The term “fluorescent dye pair” is used interchangeably with the phrase “FRET pair and / or quencher / fluorophore pair.”

[0141] In some embodiments (for example, when the probe includes a FRET pair), the probe provides a detection signal before it is cut, and when the probe is cut, the amount of detection signal measured is reduced. In some embodiments, the probe provides a first detection signal (e.g., from a FRET pair) before it is cut, and a second detection signal (e.g., from a quencher / fluorophore pair) when the probe is cut. Thus, in some embodiments, the probe includes a FRET pair and a quencher / fluorophore pair.

[0142] In some embodiments, the probe includes a FRET pair. FRET is a process in which non-radiative energy transfer occurs from an excited fluorophore to a nearby second chromophore. The range in which energy transfer can occur is limited to about 10 nanometers (100 angstroms), and the efficiency of the transfer is extremely sensitive to the isolation distance between the fluorophores. Therefore, as used herein, the term “FRET” (also known as “fluorescence resonance energy transfer” or “Förster resonance energy transfer”) may refer to a physical phenomenon involving a donor fluorophore and a matching acceptor fluorophore, where the donor emission spectrum is selected to overlap with the acceptor excitation spectrum, and a portion of the energy is transferred from the donor to the acceptor via a quantum coupling effect, so that when the donor and acceptor are in close proximity to each other (typically 10 nm or less), the excitation of the donor causes the excitation of the acceptor and the emission from the acceptor. Therefore, the FRET signal is used as a proximity gauge for the donor and acceptor; the signal is generated only when they are in close proximity to each other. In this specification, the FRET donor portion (e.g., donor fluorophore) and the FRET acceptor portion (e.g., acceptor fluorophore) are collectively referred to as a "FRET pair".

[0143] In this specification, a donor-acceptor pair (FRET donor portion and FRET acceptor portion) is referred to as a "FRET pair" or "signal FRET pair." Therefore, in some embodiments, if one signal partner is a FRET donor portion and the other signal partner is a FRET acceptor portion, the probe comprises two signal partners (signal pair). Thus, if the signal partners are in close proximity (e.g., on the same RNA molecule), a probe comprising such a FRET pair (FRET donor portion and FRET acceptor portion) will exhibit a detection signal (FRET signal), but if the partners are separated (e.g., after cleavage of the probe by the 5'-3' exonuclease activity of PCR polymerase (e.g., Taq)), the signal will be reduced (or absent). Those skilled in the art will know that FRET donor and FRET acceptor parts (FRET pairs) are publicly known, and any convenient FRET pair (e.g., any convenient pair of donor and acceptor parts) can be used.

[0144] In some embodiments, one signal partner of a signal extinction pair is an extinction portion that provides a detection signal, and the other signal partner extincts the detection signal of the first signal partner (for example, if the signal partners are close to each other, for example, if the signal partners of a signal pair are close to each other, the extinction portion extincts the signal of the signal portion so that the signal from the signal portion is reduced (extinctized)).

[0145] For example, in some embodiments, the amount of detection signal increases when the probe is cleaved. For example, in some embodiments, if both are present on the same ssDNA molecule, the signal presented by one signal partner (signal portion, fluorescent portion) is quenched by the other signal partner (quencher signal portion, fluorescent quenching portion) before cleavage by the 5'-3' exonuclease activity of PCR polymerase (e.g., Taq). In this specification, such a signal pair is referred to as a "quencher / fluorophore pair," a "quenching pair," or a "signal quenching pair." For example, in some embodiments, one signal partner (e.g., a first signal partner) is a signal portion that produces a detection signal, which is quenched by a second signal partner (e.g., a quenching portion). Therefore, such a quencher / fluorophore pair signal partner will produce a detection signal when the partners are separated (e.g., after the probe is cleaved by the 5'-3' exonuclease activity of PCR polymerase (e.g., Taq)), but the signal will be quenched when the partners are in close proximity (e.g., before the probe is cleaved by the 5'-3' exonuclease activity of PCR polymerase (e.g., Taq)).

[0146] The quenching portion can quench the signal from the signal portion to varying degrees (for example, before the probe is cleaved by the 5'-3' exonuclease activity of PCR polymerase (e.g., Taq)). In some embodiments, the quenching portion quenches the signal from the signal portion if the signal detected in the presence of the quenching portion (when the signal partners are in close proximity to each other) is 95% or less of the signal detected in the absence of the quenching portion (when the signal partners are separated). For example, in some embodiments, the signal detected in the presence of the quenching portion may be 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the signal detected in the absence of the quenching portion. In some embodiments, in the presence of extinguishing areas, no signal (e.g., a signal above the background) is detected.

[0147] In some embodiments, the signal detected in the absence of the extinction portion (when the signal partners are separated) is at least 1.2 times greater than the signal detected in the presence of the extinction portion (when the signal partners are in close proximity to each other) (for example, at least 1.3 times, at least 1.5 times, at least 1.7 times, at least 2 times, at least 2.5 times, at least 3 times, at least 3.5 times, at least 4 times, at least 5 times, at least 7 times, at least 10 times, at least 20 times, or at least 50 times greater, or a multiple of a number or range between any two of these values).

[0148] In some embodiments, the signal portion is a fluorescent label. In some such embodiments, the quenching portion quenches the signal from the fluorescent label (e.g., a light signal) (e.g., by absorbing energy within the emission spectrum of the label). Therefore, if the quenching portion is not in close proximity to the signal portion, the signal is not absorbed by the quenching portion, and thus the emission (signal) from the fluorescent label is detectable. Any convenient donor / acceptor pair (signal portion / quenching portion pair) can be used, and many suitable pairs are known in the art. In some embodiments, the quenching portion absorbs energy from the signal portion (also referred herein as the “detection label” or “detection portion”) and then emits a signal (e.g., light of a different wavelength). Thus, in some embodiments, the quenching portion is itself the signal portion (e.g., the signal portion may be 6-carboxyfluorescein, while the quenching portion is 6-carboxytetramethylrhodamine), and in some such embodiments, the pair may also be a FRET pair. In some embodiments, the quenching portion is a dark quencher. The dark quencher is capable of absorbing excitation energy and dissipating that energy in a different form (e.g., as heat). Thus, the dark quencher itself produces minimal to zero fluorescence (it does not emit fluorescence). In some embodiments, probe disconnection can be detected by measuring a colorimetric readout. For example, fluorophore release (e.g., release from a FRET pair, release from a quencher / fluorophore pair, etc.) can result in a wavelength shift (and thus a color shift) of the detection signal. Therefore, in some embodiments, probe disconnection can be detected by a color shift. Such a shift may manifest as a loss of signal intensity for one color (wavelength), an increase in signal intensity for another color, or a change in the distribution from one color to another.

[0149] In some embodiments, a method is provided for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample. In some embodiments, the method includes the step of contacting the sample with a plurality of primer pairs, wherein the plurality of primer pairs are at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, and each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of SEQ ID NOs: 1, 2, 3, 4, 5%, 96%, 97%, 98%, 99%, 100%, or 1. At least one primer pair comprising a sequence exhibiting at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 16-25; at least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, At least one primer pair wherein each primer in the at least one primer pair contains a sequence that exhibits at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 31 to 39;The invention also includes at least one primer pair capable of hybridizing to the meningococcal crtA gene, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 45 to 54. The method may include, if the sample contains either or both Streptococcus pneumoniae and Neisseria meningitidis, the step of producing a unit replication sequence of the lytA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the cpsA gene sequence of Streptococcus pneumoniae, a unit replication sequence of the sodC gene sequence of Neisseria meningitidis, a unit replication sequence of the crtA gene sequence of Neisseria meningitidis, or any combination thereof, derived from the sample. The method may also include the step of determining the presence or amount of one or more unit replication sequences in the sample as an indicator of the presence of either or both Streptococcus pneumoniae and Neisseria meningitidis. The method may include the steps of: contacting a sample with at least one pair of control primers capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer in the pair of at least one control primers contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 60–69 and 130–132; producing a unit replica sequence of the IAC derived from the sample; and determining the presence or amount of the unit replica sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is brought into contact with a composition comprising multiple primer pairs and at least one control primer pair capable of hybridizing to an IAC.

[0150] The type of sample may vary; for example, a sample may be a biological sample, an environmental sample, or derived from either. Environmental samples may be obtained from food samples, beverage samples, paper surfaces, cloth surfaces, metal surfaces, wood surfaces, plastic surfaces, soil samples, freshwater samples, wastewater samples, saline samples, exposure to air or other gaseous samples, cultures of these, or any combination thereof. Biological samples may be obtained from tissue samples, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural fluid, serumoma, pus, skin swabs or mucosal surfaces, cultures of these, or any combination thereof. Biological samples may include blood samples, respiratory samples, and / or cultures of these.

[0151] In some embodiments, the multiple primer pairs may include a first primer containing the sequence of SEQ ID NOs: 1, 3, 5, 7, or 9; a second primer containing the sequence of SEQ ID NOs: 2, 4, 6, 8, or 10; a third primer containing the sequence of SEQ ID NOs: 16, 18, 20, 22, or 24; a fourth primer containing the sequence of SEQ ID NOs: 17, 19, 21, 23, or 25; a fifth primer containing the sequence of SEQ ID NOs: 31, 33, 35, 36, or 38; a sixth primer containing the sequence of SEQ ID NOs: 32, 34, 37, or 39; a seventh primer containing the sequence of SEQ ID NOs: 45, 47, 49, 51, or 53; and an eighth primer containing the sequence of SEQ ID NOs: 46, 48, 50, 52, or 54. The multiple primer pairs may include a ninth primer containing the sequence of SEQ ID NOs. 60, 62, 64, 66, 68, or 131, and a tenth primer containing the sequence of SEQ ID NOs. 61, 63, 65, 67, 69, 130, or 132.

[0152] In some embodiments, primer pairs capable of hybridizing to the lytA gene of Streptococcus pneumoniae are SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, or SEQ ID NOs: 9 and 10; primer pairs capable of hybridizing to the cpsA gene of Streptococcus pneumoniae are SEQ ID NOs: 16 and 17, SEQ ID NOs: 18 and 19, SEQ ID NOs: 20 and 21, SEQ ID NOs: 22 and 23, or SEQ ID NOs: 24 and 25; primer pairs capable of hybridizing to the sodC gene of Neisseria meningitidis are SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 32, SEQ ID NOs: 36 and 37, or SEQ ID NOs: 38 and 39; primer pairs capable of hybridizing to the crtA gene of Neisseria meningitidis are SEQ ID NOs: 45 and 46, SEQ ID NOs: 47 and 48, SEQ ID NOs: 49 and 50, SEQ ID NOs: 51 and 52, or SEQ ID NOs: 53 and 54. In some embodiments, control primer pairs capable of hybridizing to IAC are SEQ ID NOs: 60 and 61, 62 and 63, 64 and 65, 66 and 67, 68 and 69, 61 and 130, or 131 and 132.

[0153] Amplification can be performed using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-persistent sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA). PCR may be real-time PCR. PCR may be quantitative real-time PCR (QRT-PCR). Each primer may contain an exogenous nucleotide sequence.

[0154] In some embodiments, the step of determining the presence or amount of one or more unit replica sequences includes contacting the unit replica sequences with multiple oligonucleotide probes, each of which includes a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. Each of the multiple oligonucleotide probes may contain a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. Each of the multiple oligonucleotide probes may consist of a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. Each probe may be flanked by complementary sequences at its 5' and 3' ends. In some embodiments, one of the complementary sequences contains a fluorescent moiety, and the other contains a fluorescent quenching moiety. In some embodiments, at least one of the multiple oligonucleotide probes contains both a fluorescent moiety and a fluorescent quenching moiety.

[0155] In some embodiments, a method is provided for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample. In some embodiments, the method is a step of contacting the sample with a plurality of primer pairs, the plurality of primer pairs being at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer in the at least one primer pair has at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of SEQ ID NOs. At least one primer pair containing a sequence exhibiting the following characteristics; at least one primer pair capable of hybridizing to the fucK gene of Haemophilus influenzae, wherein each primer in the at least one primer pair contains a sequence exhibiting at least approximately 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 88 to 95; M.At least one primer pair capable of hybridizing to the copB gene of Catarrhalis, wherein each primer in the at least one primer pair contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 101 to 110; and Klebsiella pneumoniae The step includes at least one primer pair capable of hybridizing to the gltA gene of a bacterium, wherein each primer in the at least one primer pair contains a sequence that exhibits at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 116 to 124. The method may include the step of producing, when the sample contains one or more species from among Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae, a unit replication sequence of the nuc gene sequence of Staphylococcus aureus, a unit replication sequence of the fucK gene sequence of Haemophilus influenzae, a unit replication sequence of the copB gene sequence of M. catarrhalis, a unit replication sequence of the gltA gene sequence of Klebsiella pneumoniae, or any combination thereof, derived from the sample.The procedure may include a step of determining the presence or amount of one or more unit replication sequences of catarrhalis and Klebsiella pneumoniae as an indicator of the presence of one or more of these species. The method may include the steps of: contacting a sample with at least one pair of control primers capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer in the pair of at least one control primers contains a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences of sequence numbers 60–69 and 130–132; producing a unit replica sequence of the IAC derived from the sample; and determining the presence or amount of the unit replica sequence of the IAC as an indicator of the performance of the assay involving the sample. In some embodiments, the sample is brought into contact with a composition comprising multiple primer pairs and at least one control primer pair capable of hybridizing to an IAC.

[0156] The multiple primer pairs may include a first primer containing the sequence of SEQ ID NOs. 75, 77, 79, 81, or 83; a second primer containing the sequence of SEQ ID NOs. 76, 78, 80, or 82; a third primer containing the sequence of SEQ ID NOs. 88, 90, 92, 93, or 94; a fourth primer containing the sequence of SEQ ID NOs. 89, 91, or 95; a fifth primer containing the sequence of SEQ ID NOs. 101, 103, 105, 107, or 109; a sixth primer containing the sequence of SEQ ID NOs. 102, 104, 106, 108, or 110; a seventh primer containing the sequence of SEQ ID NOs. 116, 118, 120, or 122; and an eighth primer containing the sequence of SEQ ID NOs. 117, 119, 121, 123, or 124. The multiple primer pairs may include a ninth primer containing the sequence of SEQ ID NOs. 60, 62, 64, 66, 68, or 131, and a tenth primer containing the sequence of SEQ ID NOs. 61, 63, 65, 67, 69, 130, or 132.

[0157] In some embodiments, primer pairs capable of hybridizing to the nuc gene of Staphylococcus aureus are SEQ ID NOs. 75 and 76, SEQ ID NOs. 77 and 78, SEQ ID NOs. 79 and 80, SEQ ID NOs. 81 and 82, or SEQ ID NOs. 83 and 78; primer pairs capable of hybridizing to the fucK gene of Haemophilus influenzae are SEQ ID NOs. 88 and 89, SEQ ID NOs. 90 and 91, SEQ ID NOs. 92 and 89, SEQ ID NOs. 93 and 89, or SEQ ID NOs. 94 and 95; M. cata Primer pairs capable of hybridizing to the copB gene of *Laris* are SEQ ID NOs: 101 and 102, SEQ ID NOs: 103 and 104, SEQ ID NOs: 105 and 106, SEQ ID NOs: 107 and 108, or SEQ ID NOs: 109 and 110; primer pairs capable of hybridizing to the glTA gene of *Klebsiella pneumoniae* are SEQ ID NOs: 116 and 117, SEQ ID NOs: 118 and 119, SEQ ID NOs: 120 and 121, SEQ ID NOs: 122 and 123, or SEQ ID NOs: 116 and 124. In some embodiments, control primer pairs capable of hybridizing to IAC are SEQ ID NOs: 60 and 61, SEQ ID NOs: 62 and 63, SEQ ID NOs: 64 and 65, SEQ ID NOs: 66 and 67, SEQ ID NOs: 68 and 69, SEQ ID NOs: 61 and 130, or SEQ ID NOs: 131 and 132.

[0158] In some embodiments, the step of determining the presence or amount of one or more unit replica sequences includes contacting the unit replica sequences with multiple oligonucleotide probes, each of which includes a sequence selected from the group consisting of SEQ ID NOs. 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs. Each of the multiple oligonucleotide probes may contain a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. Each of the multiple oligonucleotide probes may consist of a sequence selected from the group consisting of SEQ ID NOs: 84-87, 96-100, 111-115, 125-129, 70-74, and 133-134. Each probe may be flanked by complementary sequences at its 5' and 3' ends. In some embodiments, one of the complementary sequences contains a fluorescent moiety, and the other contains a fluorescent quenching moiety. At least one of the multiple oligonucleotide probes may contain both a fluorescent moiety and a fluorescent quenching moiety.

[0159] As described herein, amplification may be performed by real-time PCR, for example, quantitative real-time PCR (QRT-PCR). Primers suitable for use in the methods and compositions described herein may include exogenous nucleotide sequences that enable post-amplification manipulation of the amplification product without significantly affecting the amplification itself. In some embodiments, the primer and / or probe may be flanked by complementary sequences including a fluorophore at the 5' end and a fluorescent quencher at the 3' end. Any of the oligonucleotide probes disclosed herein may include a fluorescent moiety, a fluorescent quenching moiety, or both.

[0160] This specification discloses a method suitable for automation, thereby providing a high-throughput option for the detection and / or quantification of Streptococcus pneumoniae and Neisseria meningitidis in a sample, and / or a high-throughput option for the detection and / or quantification of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae. Various multiplex PCR platforms, such as the BD MAX® platform, Viper® platform, or Viper® LT platform, may be used to carry out one or more steps of the disclosed method. The method may be carried out in a multiplex manner. For example, nucleic acid amplification and / or detection may, in some embodiments, involve the performance of multiplex PCR. [Examples]

[0161] The following examples are provided to illustrate the specific circumstances and settings to which the present technology may be applied and are not intended to limit the scope of the present invention and the claims contained herein.

[0162] (Example 1) Detection of Streptococcus pneumoniae and Neisseria meningitidis, as well as Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae. The studies described in this embodiment describe examples of the implementation of the compositions and methods presented herein on a fully automated BD MAX system. The compositions and methods disclosed herein can also be performed on other real-time PCR analyzers, such as the ABI 7500.

[0163] Materials and methods A total of 28 strains were used to validate multiplex PCR, and these are shown in Table 8. These isolates included 15 Gram-negative strains and 13 Gram-positive strains. The six control strains used in this study were Streptococcus pneumoniae ATCC 49619, Neisseria meningitidis ATCC 13090, Moraxella catarrhalis ATCC 25238, Klebsiella pneumoniae ATCC 13439, and Haemophilus influenzae ATCC 49247. EDTA blood was obtained from healthy human volunteers.

[0164] [Table 8-1] [Table 8-2]

[0165] This study utilized the BD MAX® ExK® TNA-2 Extraction Kit, 5×qPCR Mastermix, and lysis buffer. All target gene sequences were based on alignments of available sequences deposited in the NCBI nucleotide database (https: / / www.ncbi.nlm.nih.gov / nucleotide / ). All primers and probes were designed using Beacon Designer V8.20 and synthesized by Sangon Biotech (Shanghai, China). NCBI BLASTn was used to computer-based checks of specificity and sensitivity. To extract DNA from blood samples, 1 ml of EDTA-treated blood samples (spiked with bacteria) were pre-treated with optimized lysis buffer and added to a test tube for BD MAX sample buffer. Automated DNA extraction on BD MAX using the BD MAX ExK TNA-2 Extraction Kit was performed according to the kit instructions. A multiplex PCR reaction, including the primer / probe combinations disclosed herein, was performed in a total volume of 12.5 µl containing 5 μl of a commercially available multiplex PCR master mix, 2.5 μl of nuclease-free water, the primers disclosed herein to a final concentration of 0.3 μM, and the hybridization probes disclosed herein to a final concentration of 0.2 μM. A conical test tube containing 12.5 µl of the mixture was snap-fixed to a BD MAX TNA extraction strip. The final PCR reaction was prepared by automatically adding 12.5 µl of purified DNA, prepared as described above, to the conical test tube using a BD MAX and mixing. The PCR thermal cycling profile was as follows: denaturation at 95°C for 5 minutes; and 40 cycles of denaturation at 95°C for 15 seconds, annealing and extension at 60°C for 43 seconds.

[0166] Amplification efficiency test Six control strain culture suspensions, each containing 10 µl of the above-mentioned control strains, were spiked into 1 ml of negative EDTA blood samples and pre-treated before extraction. These were examined in six independent trials at six different bacterial concentrations, starting from a 2.5 McFarland standard, with two samples per trial. Colony counting was performed using standard plate counting procedures (Tables 9-11). Robust amplification efficiencies were observed for two assays (Table 13) using the primer / probe combinations presented herein (Table 12).

[0167] [Table 9]

[0168] [Table 10]

[0169] [Table 11]

[0170] [Table 12]

[0171] [Table 13]

[0172] Analysis sensitivity test To estimate the detection limit of the optimized multiplex PCR assay presented herein (Table 13), 10 μl each of six control strain culture suspensions described above were spiked into 1 ml of negative EDTA blood samples and pre-treated before extraction. These were examined in six independent trials at six different bacterial concentrations, starting from a 2.5 McFarland standard, in two replicates per trial. Colony counting was performed using a standard plate counting procedure (Tables 14-16). The largest 10-fold dilution at which a threshold cycle (CT value) was observed was further diluted in three 2-fold dilution series (1:2, 1:4, and 1:8) to find the lowest concentration at which a CT value was detected. The lowest concentration yielding a CT value was examined in six replicates to determine the limit of detection (LoD) of the assay (Table 17). Robust analytical sensitivity was observed for each target using the primer / probe combinations presented herein.

[0173] [Table 14]

[0174] [Table 15]

[0175] [Table 16]

[0176] [Table 17]

[0177] Analytical specificity test Analytical specificity was measured using test DNA extracted from the panel of positive and negative control isolates shown in Table 8. This panel consisted of 28 control isolates representing a wide range of pathogenic isolates that are closely related to the target species or are commonly found in respiratory samples from febrile patients and identified using culture methods. As shown in Tables 18-21, the assay accurately detected all target isolates (Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, M. catarrhalis, Neisseria meningitidis, and Klebsiella pneumoniae) using the primer / probe combinations presented herein, and no cross-reactivity with non-target isolates listed in Table 8 was observed.

[0178] [Table 18]

[0179] [Table 19]

[0180] [Table 20]

[0181] [Table 21]

[0182] Terminology In at least some of the embodiments already described, one or more elements used in the embodiments may be used interchangeably in other embodiments, provided that such substitutions are not technically impossible to implement. Those skilled in the art will understand that a variety of other omissions, additions, and modifications may be made to the methods and structures described above, provided that they do not deviate from the scope of the claimed subject matter. All such modifications and changes are intended to remain within the scope of the subject matter defined by the accompanying claims.

[0183] In this specification, with respect to substantially any use of plural and / or singular terms, a person skilled in the art may, depending on the context and / or application, paraphrase from plural to singular and / or from singular to plural. For clarity, various singular / plural reinterpretations may be explicitly shown here. As used here and in the accompanying claims, unless indicated otherwise by the context, the singular “a,” “an,” and “it” include the plural referent. Unless otherwise stated, any reference to “or” here is intended to include “and / or.”

[0184] Those skilled in the art will generally understand that the terms used herein, and in particular in the accompanying claims (e.g., the text of the accompanying claims), are generally intended to be “open” terms (for example, the term “including” is to be interpreted as “including but not limited to,” the term “having” is to be interpreted as “having at least,” and the term “including” is to be interpreted as “including but not limited to.”). Those skilled in the art will further understand that where there is an intention to specify the number of claims introduced, such intention is explicitly stated in the claims, and in the absence of such statement, such intention is also absent. For example, for the sake of understanding, the following accompanying claims may include the use of introductory phrases, “at least one” and “one or more,” to introduce the claim statements. However, the use of such phrases should not be considered to imply that the introduction of a claim statement by the indefinite article "a" or "an" is limited to any particular claim containing such an introduction of a claim statement to only one such statement, even if the same claim contains an introductory phrase such as "one or more" or "at least one," and an indefinite article such as "a" or "an" (for example, "a" and / or "an" shall be interpreted as meaning "at least one" or "one or more"). The same applies to the use of the definite article used to introduce a claim statement. In addition, even if a statement of the specific number of the introduced claim is made explicitly, a person skilled in the art will recognize that such a statement should be interpreted as meaning at least the number of claims stated (for example, a statement of "two claims" alone, without other modifiers, means at least two claims, or two or more claims).Furthermore, when similar idiomatic expressions are used, such constructions are generally intended to be understood by those skilled in the art, including but not limited to systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or systems having A, B and C together. Those skilled in the art will further understand that virtually any disjunctive language and / or disjunctive phrase, whether in the description, claims, or drawings, that presents two or more alternative terms, should be understood to imply the possibility of including one of the terms, one of the terms, or both of the terms. For example, the phrase "A or B" will be understood to imply the possibility of including "A" or "B" or "A and B".

[0185] In addition, if any feature or aspect of the present disclosure is described in relation to the Markush Group, a person skilled in the art will recognize that the present disclosure is also described in relation to any individual member of the Markush Group or a subgroup of a member.

[0186] As will be understood by those skilled in the art, for all purposes, for example, with respect to providing a written description, all ranges disclosed herein also include any and all possible subranges, as well as combinations of these subranges. Any recited range can be readily recognized as fully describing the same range and enabling it to be divided, for example, into at least equal halves, thirds, quarters, fifths, tenths, etc. By way of non-limiting example, each range discussed herein can be readily divided, for example, into lower thirds, middle thirds, and upper thirds. As will also be understood by those skilled in the art, all expressions such as "less than or equal to", "at least", "greater than", "less than", etc., include the recited number and then refer to ranges that can be divided into the subranges discussed above. Finally, as will be understood by those skilled in the art, a range includes each individual member. Thus, for example, a group having 1 to 3 items refers to a group having 1, 2, or 3 items. Similarly, a group having 1 to 5 items refers to a group having 1, 2, 3, 4, or 5 items, and so on.

[0187] Although various aspects and embodiments are disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments are disclosed herein for purposes of illustration and not of limitation, and the true scope and spirit are pointed out by the following claims.

Claims

1. 1. A method for detecting S. pneumoniae and N. meningitidis in a sample, comprising: contacting the sample with a plurality of primer pairs, the plurality of primer pairs comprising: at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 1-10, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 1-10; at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 16-25, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 16-25; At least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 31-39, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 31-39; and At least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 45-54, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 45-54. a step comprising: generating an amplicon of a lytA gene sequence of S. pneumoniae, an amplicon of a cpsA gene sequence of S. pneumoniae, an amplicon of a sodC gene sequence of N. meningitidis, an amplicon of a crtA gene sequence of N. meningitidis, or any combination thereof, from the sample if the sample contains one or both of S. pneumoniae and N. meningitidis; and determining the presence or amount of one or more amplicons as an indication of the presence of one or both of Streptococcus pneumoniae and Neisseria meningitidis in said sample. The method includes:

2. Contacting the sample with at least one control primer pair capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 60-69 and 130-132, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 60-69 and 130-132; and generating amplicons of IACs derived from said sample; and Determining the presence or amount of an amplicon of the IAC as an indication of the performance of the assay using the sample. The method of claim 1 further comprising:

3. 3. The method of claim 2, wherein the sample is contacted with a composition comprising a plurality of primer pairs and at least one control primer pair capable of hybridizing to the IAC.

4. The sample is a biological sample or an environmental sample, and optionally (i) the environmental sample may be obtained from a food sample, a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a waste water sample, a salt water sample, exposure to air or other gas samples, cultures thereof, or any combination thereof; (ii) the biological sample may be obtained from a tissue sample, saliva, blood, plasma, serum, faeces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural fluid, seroma, pus, a swab of skin or a mucosal surface, a culture thereof, or any combination thereof; and / or (iii) the biological sample may include a blood sample, a respiratory sample, and / or a culture thereof; The method according to any one of claims 1 to 3.

5. The method according to any one of claims 1 to 4, wherein the plurality of primer pairs comprise a first primer comprising a sequence of SEQ ID NO: 1, 3, 5, 7, or 9; a second primer comprising a sequence of SEQ ID NO: 2, 4, 6, 8, or 10; a third primer comprising a sequence of SEQ ID NO: 16, 18, 20, 22, or 24; a fourth primer comprising a sequence of SEQ ID NO: 17, 19, 21, 23, or 25; a fifth primer comprising a sequence of SEQ ID NO: 31, 33, 35, 36, or 38; a sixth primer comprising a sequence of SEQ ID NO: 32, 34, 37, or 39; a seventh primer comprising a sequence of SEQ ID NO: 45, 47, 49, 51, or 53; and an eighth primer comprising a sequence of SEQ ID NO: 46, 48, 50, 52, or 54.

6. The method of claim 5, wherein the multiple primer pairs include a ninth primer comprising the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a tenth primer comprising the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

7. Primer pairs capable of hybridizing to the lytA gene of Streptococcus pneumoniae are SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, or SEQ ID NOs: 9 and 10; Primer pairs capable of hybridizing to the cpsA gene of Streptococcus pneumoniae are SEQ ID NOs: 16 and 17, SEQ ID NOs: 18 and 19, SEQ ID NOs: 20 and 21, SEQ ID NOs: 22 and 23, or SEQ ID NOs: 24 and 25; Primer pairs capable of hybridizing to the sodC gene of Neisseria meningitidis are SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 32, SEQ ID NOs: 36 and 37, or SEQ ID NOs: 38 and 39; Primer pairs capable of hybridizing to the crtA gene of Neisseria meningitidis are SEQ ID NOs: 45 and 46, 47 and 48, 49 and 50, 51 and 52, or 53 and 54; The method according to any one of claims 1 to 6.

8. 8. The method of any one of claims 1 to 7, wherein the control primer pairs capable of hybridizing to the IAC are SEQ ID NOs: 60 and 61, SEQ ID NOs: 62 and 63, SEQ ID NOs: 64 and 65, SEQ ID NOs: 66 and 67, SEQ ID NOs: 68 and 69, SEQ ID NOs: 61 and 130, or SEQ ID NOs: 131 and 132. (i) the amplification is carried out using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA), and optionally, the PCR may be real-time PCR or quantitative real-time PCR (QRT-PCR); and / or (ii) each primer comprises an exogenous nucleotide sequence; The method according to any one of claims 1 to 8.

10. 10. The method of any one of claims 1 to 9, wherein the step of determining the presence or amount of one or more amplicons comprises contacting the amplicon with a plurality of oligonucleotide probes, each of the plurality of oligonucleotide probes comprising a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134.

11. 11. The method of claim 10, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134. (i) each probe is flanked by a complementary sequence at its 5' end and a complementary sequence at its 3' end, one complementary sequence optionally containing a fluorescent moiety and the other complementary sequence containing a fluorescent quenching moiety; or (ii) at least one of the plurality of oligonucleotide probes comprises a fluorescent emitting moiety and a fluorescent quenching moiety; The method of claim 11.

13. A composition for detecting Streptococcus pneumoniae and Neisseria meningitidis in a sample, comprising: at least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 1-10, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 1-10; at least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 16-25, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 16-25; At least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 31-39, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 31-39; and At least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 45-54, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 45-54. A composition comprising:

14. 14. The composition of claim 13, further comprising at least one control primer pair capable of hybridizing to an internal amplification control (IAC), wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 60-69 and 130-132, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 60-69 and 130-132.

15. At least one primer pair capable of hybridizing to the lytA gene of Streptococcus pneumoniae comprises a primer comprising a sequence of SEQ ID NO: 1, 3, 5, 7, or 9, and a primer comprising a sequence of SEQ ID NO: 2, 4, 6, 8, or 10; At least one primer pair capable of hybridizing to the cpsA gene of Streptococcus pneumoniae comprises a primer comprising the sequence of SEQ ID NO: 16, 18, 20, 22, or 24, and a primer comprising the sequence of SEQ ID NO: 17, 19, 21, 23, or 25; At least one primer pair capable of hybridizing to the sodC gene of Neisseria meningitidis comprises a primer comprising the sequence of SEQ ID NO: 31, 33, 35, 36, or 38, and a primer comprising the sequence of SEQ ID NO: 32, 34, 37, or 39; At least one primer pair capable of hybridizing to the crtA gene of Neisseria meningitidis comprises a primer comprising the sequence of SEQ ID NO: 45, 47, 49, 51, or 53, and a primer comprising the sequence of SEQ ID NO: 46, 48, 50, 52, or 54; The composition according to any one of claims 13 to 14.

16. The composition according to any one of claims 14 to 15, wherein at least one control primer pair capable of hybridizing to the IAC comprises a primer comprising the sequence of SEQ ID NO: 60, 62, 64, 66, 68, or 131, and a primer comprising the sequence of SEQ ID NO: 61, 63, 65, 67, 69, 130, or 132.

17. The composition of any one of claims 13 to 16, further comprising a plurality of oligonucleotide probes, each of the plurality of oligonucleotide probes comprising a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 11-15, 26-30, 40-44, 55-59, 70-74, and 133-134.

18. 20. The composition of claim 17, wherein at least one of the plurality of probes comprises a fluorescent moiety and a fluorescent quenching moiety.

19. 1. A method for detecting S. aureus, H. influenzae, M. catarrhalis, and K. pneumoniae in a sample, comprising: Contacting the sample with a plurality of primer pairs, the plurality of primer pairs comprising: at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 75-83, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 75-83; at least one primer pair capable of hybridizing to a fucK gene of Haemophilus influenzae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 88-95, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 88-95; At least one primer pair capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 101-110, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 101-110; and At least one primer pair capable of hybridizing to the gltA gene of Klebsiella pneumoniae, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 116-124, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 116-124. a step comprising: generating an amplicon of a nuc gene sequence of S. aureus, an amplicon of a fucK gene sequence of H. influenzae, an amplicon of a copB gene sequence of M. catarrhalis, an amplicon of a gltA gene sequence of K. pneumoniae, or any combination thereof, from the sample, if the sample comprises one or more of S. aureus, H. influenzae, M. catarrhalis, and K. pneumoniae; and determining the presence or amount of one or more amplicons as an indication of the presence of one or more of Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in the sample. The method includes:

20. Contacting the sample with at least one control primer pair capable of hybridizing to an internal amplification control (IAC) added to the sample, wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 60-69 and 130-132, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 60-69 and 130-132; and generating amplicons of IACs derived from said sample; and Determining the presence or amount of an amplicon of the IAC as an indication of the performance of the assay using the sample.

20. The method of claim 19, further comprising:

21. A composition for detecting Staphylococcus aureus, Haemophilus influenzae, M. catarrhalis, and Klebsiella pneumoniae in a sample, comprising: at least one primer pair capable of hybridizing to the nuc gene of Staphylococcus aureus, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 75-83, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 75-83; at least one primer pair capable of hybridizing to a fucK gene of Haemophilus influenzae, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 88-95, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 88-95; At least one primer pair capable of hybridizing to the copB gene of M. catarrhalis, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 101-110, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 101-110; and At least one primer pair capable of hybridizing to the gltA gene of Klebsiella pneumoniae, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 116-124, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 116-124. A composition comprising:

22. 22. The composition of claim 21, further comprising at least one control primer pair capable of hybridizing to an internal amplification control (IAC), wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 60-69 and 130-132, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 60-69 and 130-132.